

A Modular Synthesis of Functionalised Phenol Enabled by Controlled Boron Speciation

John J. Molloy,^a Robert P. Law,^{a,b} James W. B. Fyfe,^a Ciaran P. Seath,^a David J. Hirst,^b and Allan J. B. Watson^{a*}

^a WestCHEM, Department of Pure and Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow, G1 1XL, UK.

^b GlaxoSmithKine, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK.

Contents

1. General
2. General Experimental Procedures
3. Reaction Optimisation Data
 - 3.1 Oxidation of BPin – Oxidant Study
 - 3.2 Oxidation of BMIDA – Oxidant Study
 - 3.3 BPin Oxidant Equivalent/Temperature Study
 - 3.4 BMIDA Oxidant Equivalent/Temperature Study
 - 3.5 BPin Oxidation Time Study
4. Compound Characterisation Data
 - 4.1 Intermediates
 - 4.2 Products from Figure 2 and Scheme 2
5. References
6. NMR and HRMS Spectra for Intermediates and Products

1. General

All reagents and solvents were obtained from commercial suppliers and were used without further purification unless otherwise stated. Purification was carried out according to standard laboratory methods.¹

1.1 Purification of Solvents

Dry THF was obtained from a PureSolv SPS-400-5 solvent purification system. This solvent was transferred to and stored in a septum-sealed oven-dried flask over previously activated 4 Å molecular sieves and purged with and stored under N₂. CH₂Cl₂, Et₂O, EtOAc, MeCN, and petroleum ether 40-60° for purification purposes were used as obtained from suppliers without further purification.

1.2 Drying of Inorganic Bases

K₃PO₄ was dried in a Heraeus Vacutherm oven at 60 °C under vacuum for a minimum of 24 hours before use.

1.3 Experimental Details

Reactions were carried out using conventional glassware (preparation of intermediates) or in capped 5 mL microwave vials (optimisation reactions and reactions for Table 1, Scheme 1, Figure 2, and Scheme 2). The glassware was oven-dried (150 °C) and purged with N₂ before use. Purging refers to a vacuum/nitrogen-refilling procedure. Room temperature was generally 18 °C. Reactions were carried out at elevated temperatures using a temperature-regulated hotplate/stirrer.

1.4 Purification of Products

Thin layer chromatography was carried out using Merck silica plates coated with fluorescent indicator UV254. These were analysed under 254 nm UV light or developed using potassium permanganate solution. Normal phase flash chromatography was carried out using ZEOprep 60 HYD 40-63 µm silica gel. Reverse phase flash chromatography was carried out using IST Isolute C18 cartridges.

1.5 Analysis of Products


Fourier Transformed Infra-Red (FTIR) spectra were obtained on a Shimadzu IRAffinity-1 machine. ¹⁹F NMR spectra were obtained on a Bruker AV 400 spectrometer at 376 MHz. ¹¹B NMR spectra were obtained on a Bruker AV 400 spectrometer at 128 MHz. ¹H and ¹³C, NMR spectra were obtained on either a Bruker AV 400 at 400 MHz and 101 MHz, respectively, or Bruker DRX 500 at 500 MHz and 126 MHz, respectively. Chemical shifts are reported in ppm and coupling constants are reported in Hz: CDCl₃ is referenced at 7.26 (¹H) and 77.0 (¹³C), DMSO-d₆ referenced at 2.50 (¹H) and 39.5 (¹³C), and CD₃CN referenced at 1.94 (¹H) and 118.3, 1.3 (¹³C). High-resolution mass spectra were

obtained through analysis at the EPSRC UK National Mass Spectrometry Facility at Swansea University. Reversed phase HPLC data was obtained on an Agilent 1200 series HPLC using a Machery-Nagel Nucleodur C18 column, which was maintained at a constant temperature of 40 °C. Analysis was performed using a gradient method, eluting with 5 – 80% MeCN/H₂O over 16 minutes at a flow rate of 2 mL/min. Samples for HPLC analysis were prepared through the addition of 2 mL of caffeine standard (to the completed reaction mixture, the resulting solution was then stirred before the removal of a 200 µL aliquot. The aliquot was diluted to 1 mL with MeCN, a 200 µL aliquot of the diluted solution was then filtered through cotton wool and further diluted with 800 µL MeCN and 500 µL H₂O for HPLC analysis against established conversion factors.

2. General Experimental Procedures

General Procedure A: Optimised Reaction (Scheme 1 and Figure 2)

For example, synthesis of [1,1'-biphenyl]-4-ol, **3a**



To an oven-dried 5 mL microwave vial was added 4-bromophenylboronic acid MIDA ester (70.6 mg, 0.226 mmol, 1 equiv), 4,4,5,5-tetramethyl-2-phenyl-1,3,2-dioxaborolane (69.3 mg, 0.339 mmol, 1.5 equiv), Pd(dppf)Cl₂·DCM (7.4 mg, 0.009 mmol, 4 mol%), and K₃PO₄ (144 mg, 0.678 mmol, 3 equiv). The vial was then capped and purged with N₂ before addition of THF (0.9 mL, 0.25 M) and H₂O (20 µL, 1.13 mmol, 5 equiv). The reaction mixture was then heated to 90 °C in a sand bath for 24 h. The reaction mixture was allowed to cool to room temperature then decapped, cooled to 0 °C, and 30% wt. aq. H₂O₂ (177 µL, 2.26 mmol, 10 equiv) was added dropwise. The reaction mixture was then stirred at room temperature for 3 h. The reaction mixture was then cooled to 0 °C and quenched with sodium metabisulphite (176 mg, 0.904 mmol, 4 equiv) before being concentrated under vacuum. The residue was then dissolved in EtOAc (10 mL) and washed with sat. aq. NH₄Cl (2x10 mL) and brine (10 mL). The aqueous washings were re-extracted with EtOAc (10 mL), the combined organics were filtered through a hydrophobic frit packed with Celite®, and concentrated under vacuum before being purified by column chromatography (C18 silica gel, 0-60% H₂O in MeCN) to afford the title compound as a white solid (31 mg, 80%).

ν_{max} (solid): 3399, 3098, 3062, 1597, 1485 cm⁻¹.


^1H NMR (CD_3CN , 500 MHz): δ 7.56-7.59 (m, 2H), 7.48-7.51 (m, 2H), 7.42 (t, J = 8.2 Hz, 2H), 7.30 (tt, J = 8.0, 2.0 Hz, 1H), 6.99 (s, 1H), 6.89 (d, J = 8.3 Hz, 2H).

^{13}C NMR ($\text{DMSO}-d_6$, 126 MHz): δ 157.1, 140.2, 130.9, 128.7, 127.7, 126.3, 125.9, 115.8.

HRMS: exact mass calculated for $[\text{M}-\text{H}]^-$ ($\text{C}_{12}\text{H}_9\text{O}$) requires m/z 169.0659, found m/z 169.0658.

General Procedure B: Optimised Reaction (Figure 2)

For example, synthesis of 3-(benzo[b]thiophen-2-yl)-5-(trifluoromethyl)phenol, **3b**



To an oven dried 5 mL microwave vial was added 3-bromo-5-(trifluoromethyl)phenylboronic acid MIDA ester (86 mg, 0.226 mmol, 1 equiv), benzo[b]thiophen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (88.2 mg, 0.339 mmol, 1.5 equiv), $\text{Pd}(\text{OAc})_2$ (2 mg, 0.009 mmol, 4 mol%), SPhos (7.4 mg, 0.018 mmol, 8 mol%), and K_3PO_4 (144 mg, 0.678 mmol, 3 equiv). The vial was then capped and purged with N_2 before addition of THF (0.9 mL, 0.25 M) and H_2O (20 μL , 1.13 mmol, 5 equiv). The reaction mixture was then heated to 90 $^\circ\text{C}$ in a sand bath for 24 h. The reaction mixture was allowed to cool to room temperature then decapped, cooled to 0 $^\circ\text{C}$, and 30% wt. aq. H_2O_2 (177 μL , 2.26 mmol, 10 equiv) was added dropwise. The reaction mixture was then stirred at room temperature for 3 h. The reaction mixture was then cooled to 0 $^\circ\text{C}$ and quenched with sodium metabisulphite (176 mg, 0.904 mmol, 4 equiv) before being concentrated under vacuum. The residue was then dissolved in EtOAc (10 mL) and washed with sat. aq. NH_4Cl (2x10 mL) and brine (10 mL). The aqueous washings were re-extracted with EtOAc (10 mL), the combined organics filtered through a hydrophobic frit packed with Celite®, and concentrated under vacuum before being purified by column chromatography (silica gel, 0-30% Et_2O in petroleum ether) to afford the title compound as an orange solid (58 mg, 88%).

ν_{max} (solid): 3305, 3067, 3052, 2923, 1610, 1450, 1439, 1351, 1327 cm^{-1} .

^1H NMR (CD_3CN , 500 MHz): δ 7.93 (d, J = 7.5 Hz, 1H), 7.86 (dd, J = 6.9, 1.6 Hz, 1H), 7.77 (s, 1H), 7.64 (s, 1H), 7.56 (s, 1H), 7.37 - 7.46 (m, 3H), 7.10 (s, 1H).


^{13}C NMR (CD_3CN , 126 MHz): δ 157.9, 141.9, 140.5, 139.4, 136.6, 132.1 (d, $^2J_{\text{C-F}} = 32.4$ Hz), 125.2, 125.0, 124.0, 123.9 (d, $^1J_{\text{C-F}} = 271.8$ Hz) 122.3, 121.4, 116.6, 114.3 (d, $^3J_{\text{C-F}} = 3.2$ Hz) 111.9 (d, $^3J_{\text{C-F}} = 3.2$ Hz).

^{19}F NMR (CD_3CN , 376 MHz): δ -64.24 (s, 3F).

HRMS: exact mass calculated for $[\text{M-H}]^-$ ($\text{C}_{15}\text{H}_8\text{F}_3\text{OS}$) requires m/z 293.0253, found m/z 293.0245.

General Procedure C: Synthesis of MIDA Esters from Boronic Acids

For example, for the preparation of 3-bromo-5-(trifluoromethyl)phenylboronic acid MIDA ester, **S1**



A mixture of 3-bromo-5-(trifluoromethyl)phenylboronic acid (2.0 g, 7.6 mmol, 1 equiv), *N*-methyliminodiacetic acid (1.17 g, 8 mmol, 1.05 equiv) in DMF (100 mL) was heated to 90 °C for 18 h under air. The reaction mixture was allowed to cool to room temperature and concentrated under vacuum to give an off-white slurry. EtOAc (100 mL) was added and the resulting precipitate was collected by filtration. The precipitate was washed with H_2O (2×50 mL) and Et_2O (2×50 mL) before being dried under vacuum to afford the title compound as a white crystalline solid (1.63 g, 57%).

ν_{max} (film): 3344, 3014, 2978, 1760, 1323, 1286, 1201, 1159, 1103, 1035 cm^{-1} .

^1H NMR (DMSO-d_6 , 400 MHz): δ 7.96 (s, 1H), 7.92 (s, 1H), 7.79 (s, 1H), 4.38 (d, $J = 17.2$ Hz, 2H), 4.21 (d, $J = 17.2$ Hz, 2H), 2.62 (s, 3H).

^{13}C NMR (DMSO-d_6 , 101 MHz): δ 169.2, 139.4, 130.4 (d, $^2J_{\text{C-F}} = 31.9$ Hz), 128.3 (d, $^3J_{\text{C-F}} = 3.7$ Hz), 128.0 (d, $^3J_{\text{C-F}} = 3.1$ Hz), 123.4 (d, $^1J_{\text{C-F}} = 272.8$ Hz), 122.2, 62.4, 48.0. Carbon bearing boron not observed.


^{11}B NMR (DMSO-d_6 , 128 MHz): δ 10.0.

^{19}F NMR (DMSO-d_6 , 376 MHz): δ -61.0 (s, 3F).

HRMS: exact mass calculated for $[\text{M+H}]^+$ ($\text{C}_{12}\text{H}_{11}\text{BBrF}_3\text{NO}_4$) requires m/z 379.9911, found m/z 379.9911.

General Procedure D: Miyaura Borylation of Aryl Bromides

For example, for the preparation of methyl 5-chloro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate, **S2**



Methyl 2-bromo-5-chlorobenzoate (3.15 g, 12.63 mmol, 1 equiv), bis(pinacolato)diboron (5.35 g, 13.89 mmol, 1.1 equiv), Pd(dppf)Cl₂·DCM (413 mg, 0.51 mmol, 4 mol%), and KOAc (3.72 g, 37.89 mmol, 3 equiv) were dissolved in 1,4-dioxane (80 mL) and degassed with N₂. The reaction was heated to 90 °C for 24 h. The mixture was cooled to room temperature, filtered through a plug of silica, washing with EtOAc (50 mL), and the filtrate evaporated. Purification of the residue by column chromatography (silica gel, 0-10% EtOAc in petroleum ether) afforded the title compound as a clear oil (2.76 g, 74%).

ν_{max} (film): 2978, 1721, 1344, 1294, 1258, 1142, 1096, 1055 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.94 (d, J = 2.0 Hz, 1H), 7.51 (dd, J = 8.0, 2.0 Hz, 1H), 7.46 (d, J = 8.0 Hz, 1H), 3.94 (s, 3H), 1.43 (s, 12H).

¹³C NMR (CDCl₃, 101 MHz): δ 166.8, 134.9, 134.8, 133.1, 131.3, 128.4, 83.8, 52.1, 24.4.

¹¹B NMR (CDCl₃, 128 MHz): δ 31.6.

HRMS: exact mass calculated for [M+H]⁺ (C₁₄H₁₉BClO₄) requires m/z 297.1059, found m/z 297.1058.

General Procedure E: Oxidation of BPin

To an oven-dried 5 mL microwave vial was added 2-([1,1'-biphenyl]-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (50 mg, 0.178 mmol, 1 equiv) and K₃PO₄ (114 mg, 0.534 mmol, 3 equiv). The reaction mixture was suspended in THF (0.6 mL, 0.3 M) and H₂O (16 μ L, 0.892 mmol, 5 equiv). 30% wt. aq. H₂O₂ (139.5 μ L, 1.78 mmol, 1 equiv) was added at 0 °C and the reaction was stirred at room temperature for 3 h. The reaction was quenched with sodium metabisulphite (135 mg, 0.712 mmol, 4 equiv) and the conversion to product(s) was determined by HPLC against an internal standard (caffeine).

General Procedure F: Oxidation of BMIDA

To an oven-dried 5 mL microwave vial was added 4-biphenylboronic acid MIDA ester (50 mg, 0.162 mmol, 1 equiv) and K_3PO_4 (103 mg, 0.486 mmol, 3 equiv). The reaction mixture was suspended in THF (0.54 mL, 0.3 M) and H_2O (14 μ L, 0.81 mmol, 5 equiv). 30% wt. aq. H_2O_2 (126.4 μ L, 1.62 mmol, 1 equiv) was added at 0 °C and the reaction was stirred at room temperature for 3 hours. The reaction was quenched with sodium metabisulphite (123 mg, 0.648 mmol, 4 equiv) and the conversion to product(s) was determined by HPLC against an internal standard (caffeine).

3. Reaction Optimisation Data

3.1 Oxidation of BPin – Oxidant Study

Reactions were carried out according to General Procedure E using 2-([1,1'-biphenyl]-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (50 mg, 0.178 mmol, 1 equiv), K_3PO_4 (114 mg, 0.534 mmol, 3 equiv), THF (0.6 mL, 0.3 M), H_2O (16 μ L, 0.892 mmol, 5 equiv), and **Oxidant** (1.78 mmol, 10 equiv).

Entry	Oxidant	Conversion
1	30% wt. aq. H_2O_2 (139.5 μ L)	98%
2	aq. Oxone® (0.54 M, 3.3 mL)	9%
3	$NaBO_3 \cdot 4H_2O$ (274.5 mg)	18%
4	NaOCl (110 μ L)	-
5	UHP (167 mg)	87%

3.2 Oxidation of BMIDA – Oxidant Study

Reactions were carried out according to General Procedure F using 4-biphenylboronic acid MIDA ester (50 mg, 0.162 mmol, 1 equiv), K_3PO_4 (103 mg, 0.486 mmol, 3 equiv), THF (0.54 mL, 0.3 M), H_2O (14 μ L, 0.81 mmol, 5 equiv), and **Oxidant** (1.62 mmol, 10 equiv).

Entry	Oxidant	Conversion
1	30% wt. aq. H_2O_2 (126.4 μ L)	10%
2	aq. Oxone® (0.54 M, 3 mL)	-
3	$NaBO_3 \cdot 4H_2O$ (274.5 mg)	1%
4	NaOCl (100 μ L)	-
5	UHP (152 mg)	2%

3.3 BPin Oxidant Equivalent/Temperature Study

Reactions were carried out according to General Procedure E using 2-([1,1'-biphenyl]-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (50 mg, 0.178 mmol, 1 equiv), K₃PO₄ (114 mg, 0.534 mmol, 3 equiv), THF (0.6 mL, 0.3 M), H₂O (16 µL, 0.892 mmol, 5 equiv), and **Oxidant (X equiv)**. Reactions were run for 24 h.

Entry	Oxidant	Temperature	Conversion
1	30% wt. aq. H ₂ O ₂ (14.0 µL, 0.178 mmol, 1 equiv)	r.t.	36%
2	30% wt. aq. H ₂ O ₂ (41.9 µL, 0.534 mmol, 3 equiv)	r.t.	71%
3	30% wt. aq. H ₂ O ₂ (69.8 µL, 0.89 mmol, 5 equiv)	r.t.	93%
4	30% wt. aq. H ₂ O ₂ (139.5 µL, 1.78 mmol, 10 equiv)	r.t.	98%
5	30% wt. aq. H ₂ O ₂ (14.0 µL, 0.178 mmol, 1 equiv)	50 °C	37%
6	30% wt. aq. H ₂ O ₂ (41.9 µL, 0.534 mmol, 3 equiv)	50 °C	84%
7	30% wt. aq. H ₂ O ₂ (69.8 µL, 0.89 mmol, 5 equiv)	50 °C	98%
8	30% wt. aq. H ₂ O ₂ (139.5 µL, 1.78 mmol, 10 equiv)	50 °C	99%
9	aq. Oxone® (0.54 M, 0.33 mL, 0.178 mmol, 1 equiv)	r.t.	6%
10	aq. Oxone® (0.54 M, 0.99 mL, 0.534 mmol, 3 equiv)	r.t.	59%
11	aq. Oxone® (0.54 M, 1.65 mL, 0.89 mmol, 5 equiv)	r.t.	50%
12	aq. Oxone® (0.54 M, 3.3 mL, 1.78 mmol, 10 equiv)	r.t.	32%
13	aq. Oxone® (0.54 M, 0.33 mL, 0.178 mmol, 1 equiv)	50 °C	4%
14	aq. Oxone® (0.54 M, 0.99 mL, 0.534 mmol, 3 equiv)	50 °C	23%
15	aq. Oxone® (0.54 M, 1.65 mL, 0.89 mmol, 5 equiv)	50 °C	42%
16	aq. Oxone® (0.54 M, 3.3 mL, 1.78 mmol, 10 equiv)	50 °C	57%

3.4 BMIDA Oxidant Equivalent/Temperature Study

Reactions were carried out according to General Procedure F using 4-biphenylboronic acid MIDA ester (50 mg, 0.162 mmol, 1 equiv), K₃PO₄ (103 mg, 0.486 mmol, 3 equiv), THF (0.54 mL, 0.3 M), H₂O (14 µL, 0.81 mmol, 5 equiv), and **Oxidant (X equiv)**. Reactions were run for 24 h.

Entry	Oxidant	Temperature	Conversion
1	30% wt. aq. H ₂ O ₂ (12.6 µL, 0.162 mmol, 1 equiv)	r.t.	5%
2	30% wt. aq. H ₂ O ₂ (37.9 µL, 0.486 mmol, 3 equiv)	r.t.	8%
3	30% wt. aq. H ₂ O ₂ (63.2 µL, 0.81 mmol, 5 equiv)	r.t.	12%
4	30% wt. aq. H ₂ O ₂ (126.4 µL, 1.62 mmol, 10 equiv)	r.t.	22%
5	30% wt. aq. H ₂ O ₂ (12.6 µL, 0.162 mmol, 1 equiv)	50 °C	34%

6	30% wt. aq. H ₂ O ₂ (37.9 μ L, 0.486 mmol, 3 equiv)	50 °C	6%
7	30% wt. aq. H ₂ O ₂ (63.2 μ L, 0.81 mmol, 5 equiv)	50 °C	7%
8	30% wt. aq. H ₂ O ₂ (126.4 μ L, 1.62 mmol, 10 equiv)	50 °C	55%
9	aq. Oxone® (0.54 M, 0.3 mL, 0.162 mmol, 1 equiv)	r.t.	3%
10	aq. Oxone® (0.54 M, 0.9 mL, 0.486 mmol, 3 equiv)	r.t.	15%
11	aq. Oxone® (0.54 M, 1.5 mL, 0.81 mmol, 5 equiv)	r.t.	26%
12	aq. Oxone® (0.54 M, 3.0 mL, 1.62 mmol, 10 equiv)	r.t.	2%
13	aq. Oxone® (0.54 M, 0.3 mL, 0.162 mmol, 1 equiv)	50 °C	3%
14	aq. Oxone® (0.54 M, 0.9 mL, 0.486 mmol, 3 equiv)	50 °C	29%
15	aq. Oxone® (0.54 M, 1.5 mL, 0.81 mmol, 5 equiv)	50 °C	70%
16	aq. Oxone® (0.54 M, 3.0 mL, 1.62 mmol, 10 equiv)	50 °C	76%

3.5 BPin Oxidation Time Study


Reactions were carried out according to General Procedure E using 2-([1,1'-biphenyl]-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (50 mg, 0.178 mmol, 1 equiv), K₃PO₄ (114 mg, 0.534 mmol, 3 equiv), THF (0.6 mL, 0.3 M), H₂O (16 μ L, 0.892 mmol, 5 equiv), and 30% wt. aq. H₂O₂ (139.5 μ L, 1.78 mmol, 10 equiv) for **X h**.

Entry	Time	Conversion
1	1.5 h	59%
2	2 h	68%
3	3 h	92%
4	18 h	93%
5	24 h	98%

4. Compound Characterisation Data

4.1 Intermediates

3-Bromo-5-(trifluoromethyl)phenylboronic acid MIDA ester, **S1**



Prepared according to General Procedure C using 3-bromo-5-(trifluoromethyl)phenylboronic acid (2.0 g, 7.6 mmol, 1 equiv) and *N*-methyliminodiacetic acid (1.17 g, 8 mmol, 1.05 equiv) in DMF (100 mL) to afford the title compound as a white crystalline solid (1.63 g, 57%).

ν_{\max} (film): 3344, 3014, 2978, 1760, 1323, 1286, 1201, 1159, 1103, 1035 cm^{-1} .

^1H NMR (DMSO- d_6 , 400 MHz): δ 7.96 (s, 1H), 7.92 (s, 1H), 7.79 (s, 1H), 4.38 (d, J = 17.2 Hz, 2H), 4.21 (d, J = 17.2 Hz, 2H), 2.62 (s, 3H).


^{13}C NMR (DMSO- d_6 , 101 MHz): δ 169.2, 139.4, 130.4 (d, $^2J_{\text{C-F}}$ = 31.9 Hz), 128.3 (d, $^3J_{\text{C-F}}$ = 3.7 Hz), 128.0 (d, $^3J_{\text{C-F}}$ = 3.1 Hz), 123.4 (d, $^1J_{\text{C-F}}$ = 272.8 Hz), 122.2, 62.4, 48.0. Carbon bearing boron not observed.

^{11}B NMR (DMSO- d_6 , 128 MHz): δ 10.0.

^{19}F NMR (DMSO- d_6 , 376 MHz): δ -61.0 (s, 3F).

HRMS: exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{12}\text{H}_{11}\text{BBBrF}_3\text{NO}_4$) requires m/z 379.9911, found m/z 379.9911.

Methyl 5-chloro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate, **S2**



Prepared according to General Procedure D using methyl 2-bromo-5-chlorobenzoate (3.15 g, 12.63 mmol, 1 equiv), bis(pinacolato)diboron (5.35 g, 13.89 mmol, 1.1 equiv), Pd(dppf) $\text{Cl}_2 \cdot \text{DCM}$ (413 mg, 0.51 mmol, 4 mol%), and KOAc (3.72 g, 13.89 mmol, 3 equiv) in 1,4-dioxane (80 mL) to afford the title compound as a clear oil (2.76 g, 74%).

ν_{\max} (film): 2978, 1721, 1344, 1294, 1258, 1142, 1096, 1055 cm^{-1} .


^1H NMR (CDCl_3 , 400 MHz): δ 7.94 (d, J = 2.0 Hz, 1H), 7.51 (dd, J = 8.0, 2.0 Hz, 1H), 7.46 (d, J = 8.0 Hz, 1H), 3.94 (s, 3H), 1.43 (s, 12H).

^{13}C NMR (CDCl_3 , 101 MHz): δ 166.8, 134.9, 134.8, 133.1, 131.3, 128.4, 83.8, 52.1, 24.4.

^{11}B NMR (CDCl_3 , 128 MHz): δ 31.6.

HRMS: exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{14}\text{H}_{19}\text{BClO}_4$) requires m/z 297.1059, found m/z 297.1058.

Potassium (4-chloro-2-(methoxycarbonyl)phenyl)trifluoroborate, **S3**



4-Chloro-2-(methoxycarbonyl)phenylboronic acid pinacol ester (**S2**, 2.7 g, 9.10 mmol, 1 equiv) was dissolved in MeOH (25 mL). Potassium hydrogen fluoride (4.5 M aq., 10.0 mL, 45.0 mmol, 5 equiv) was added and the resulting thick white slurry was stirred at room temperature for 30 min. The reaction mixture was then concentrated under vacuum. The residue was suspended in hot acetone and filtered. The filtrate was evaporated and the residue azeotroped with 1:1 MeOH:H₂O (30 mL) three times to afford the title compound (1.28 g, 51%) as a white solid.

ν_{\max} (film): 1697, 1292, 1244 cm⁻¹.

¹H NMR (DMSO-d₆, 400 MHz): δ 7.46 (d, J = 8.0 Hz, 1H), 7.25-7.29 (m, 1H), 7.21 (d, J = 2.5 Hz, 1H), 3.69 (s, 3H).


¹³C NMR (DMSO-d₆, 101 MHz): δ 170.7, 138.5, 134.8, 129.5, 128.0, 125.2, 51.5. Carbon bearing boron not observed.

¹⁹F NMR (DMSO-d₆, 376 MHz): δ -137.6 (s, 3F).

¹¹B NMR (DMSO-d₆, 128 MHz): δ 2.59.

HRMS: exact mass calculated for [M-K]⁺ (C₈H₆BClF₃O₂) requires m/z 237.0107 found m/z 237.0104.


4-Chloro-2-(methoxycarbonyl)phenylboronic acid, **S4**



Potassium (4-chloro-2-(methoxycarbonyl)phenyl)trifluoroborate (**S3**, 1.25 g, 4.52 mmol, 1 equiv) was dissolved in MeCN (45 mL). H₂O (0.24 mL, 13.56 mmol, 3 equiv) and TMSCl (1.72 mL, 13.56 mmol, 3 equiv) were added and the reaction was stirred for 1 h at room temperature, then quenched with sat. aq. NaHCO₃ (7 mL). The mixture was diluted with EtOAc (40 mL), the organics were separated and washed with water (2x20 mL), and the aqueous extracts were re-extracted with EtOAc (2x10 mL). The combined organics were dried over Na₂SO₄, filtered, and concentrated to afford the crude title compound (967 mg, 100%), which was taken forward directly to the preparation of **S5**.

^1H NMR (DMSO- d_6 , 400 MHz): δ 7.98 (br. s., 2H), 7.83 (d, J = 2.0 Hz, 1H), 7.63 (dd, J = 8.0, 2.0 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 3.83 (s, 3H).

4-Chloro-2-(methoxycarbonyl)phenylboronic acid MIDA ester, **S5**



Prepared according to General Procedure C using 4-chloro-2-(methoxycarbonyl)phenylboronic acid (crude **S4**, 915 mg, 4.27 mmol, 1 equiv) and *N*-methyliminodiacetic acid (690 mg, 4.69 mmol, 1.1 equiv) in DMF (20 mL) to afford the title compound as an off-white solid (1.10 g, 79%).

ν_{max} (film): 1763, 1740, 1724, 1346, 1315, 1290, 1236, 1188, 1148, 1030 cm^{-1} .


^1H NMR (DMSO- d_6 , 400 MHz): δ 7.55-7.62 (m, 3H), 4.39 (d, J = 17.5 Hz, 2H), 4.17 (d, J = 17.5 Hz, 2H), 3.78 (s, 3H), 2.77 (s, 3H).

^{13}C NMR (DMSO- d_6 , 101 MHz): δ 169.8, 169.4, 138.8, 136.5, 133.7, 129.8, 127.4, 63.9, 52.9, 49.4. Carbon bearing boron not observed.

^{11}B NMR (DMSO- d_6 , 128 MHz): δ 10.9.

HRMS: exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{13}\text{H}_{14}\text{BClINO}_6$) requires m/z 326.0597, found m/z 326.0596.

Methyl 2',4'-difluoro-4-hydroxy-[1,1'-biphenyl]-3-carboxylate (Diflunisal methyl ester), **S6**



Prepared according to General Procedure B using 4-chloro-2-(methoxycarbonyl)phenylboronic acid MIDA ester (81 mg, 0.25 mmol, 1 equiv), 4,4,5,5-tetramethyl-2-(2,4-difluorophenyl)-1,3,2-dioxaborolane (90 mg, 0.375 mmol, 1.5 equiv), $\text{Pd}(\text{OAc})_2$ (2.3 mg, 0.01 mmol, 4 mol%), SPhos (8.2 mg, 0.02 mmol, 8 mol%), K_3PO_4 (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H_2O (22.5 μL , 1.25 mmol, 5 equiv), and 30% wt. aq. H_2O_2 (195 μL , 2.5 mmol, 10 equiv). After 27 h, the reaction

mixture was subjected to the purification outlined in the General Procedure (silica gel, 0-5% Et₂O in petroleum ether) to afford the title compound as a white solid (33 mg, 50%).

ν_{max} (film): 3113, 1676, 1483, 1441, 1258, 1213, 1094 cm⁻¹.


¹H NMR (CDCl₃, 400 MHz): δ 10.86 (s, 1H), 8.00 (dd, J = 2.1, 1.3 Hz, 1H), 7.63 (dt, J = 8.7, 2.0 Hz, 1H), 7.39 (td, J = 8.7, 6.4 Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 6.89-7.00 (m, 2H), 4.00 (s, 3H).

¹³C NMR (CDCl₃, 101 MHz): δ 169.9, 161.7 (dd, $^1J_{\text{C-F}}$ = 250.0 Hz, $^3J_{\text{C-F}}$ = 11.0 Hz), 160.7, 159.2 (dd, $^1J_{\text{C-F}}$ = 250.0 Hz, $^3J_{\text{C-F}}$ = 11.0 Hz), 135.7, 130.6 (dd, $^3J_{\text{C-F}}$ = 11.0, 5.4 Hz), 129.7 (d, $^3J_{\text{C-F}}$ = 2.7 Hz), 125.6, 123.8 (dd, $^2J_{\text{C-F}}$ = 13.5 Hz, $J_{\text{C-F}}$ = 5.4 Hz), 117.4, 112.0, 111.2 (dd, $^2J_{\text{C-F}}$ = 21.5 Hz, $J_{\text{C-F}}$ = 2.7 Hz), 103.9 (dd, $^2J_{\text{C-F}}$ = 26.5, 26.5 Hz), 52.0.

¹⁹F NMR (CDCl₃, 376 MHz): δ -111.4 (d, J = 7.4 Hz, 1F), -113.8 (d, J = 7.4 Hz, 1F).

HRMS: exact mass calculated for [M-H]⁻ (C₁₄H₉F₂O₃) requires m/z 263.0525, found m/z 263.0520.

4-Bromo-2-fluorophenylboronic acid MIDA ester, **S7**



Prepared according to General Procedure D using 4-bromo-2-fluorophenylboronic acid (875 mg, 4 mmol, 1 equiv), *N*-methyliminodiacetic acid (618 mg, 4.2 mmol, 1.05 equiv), and DMF (50 mL) to afford the title compound as a white crystalline solid (994 mg, 75%).

ν_{max} (film): 3014, 2978, 1761, 1575, 1340, 1292, 1255, 1193, 1033 cm⁻¹.

¹H NMR (DMSO-*d*₆, 400 MHz): δ 7.40-7.48 (m, 3H), 4.42 (d, J = 17.3 Hz, 2H), 4.10 (d, J = 17.3 Hz, 2H), 2.63 (s, 3H).


¹³C NMR (DMSO-*d*₆, 101 MHz): δ 168.8, 165.3 (d, $^1J_{\text{C-F}}$ = 246.1), 136.4 (d, $^3J_{\text{C-F}}$ = 10.0 Hz), 127.4, 123.3 (d, $^3J_{\text{C-F}}$ = 10.0 Hz), 118.3 (d, $^2J_{\text{C-F}}$ = 28.8 Hz), 62.4, 47.5. Carbon bearing boron not observed.

¹¹B NMR (DMSO-*d*₆, 128 MHz): δ 10.7.

¹⁹F NMR (DMSO-*d*₆, 376 MHz): δ -102.9 (s, 1F).

HRMS: exact mass calculated for [M+H]⁺ (C₁₁H₁₁BBrFNO₄) requires m/z 329.9943, found m/z 329.9944.

Methyl 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane-1-carboxylate, **S8**



Prepared according to General Procedure D using methyl 1-(4-bromophenyl)cyclopropanecarboxylate (2.50 g, 9.8 mmol, 1 equiv), bis(pinacolato)diboron (2.51 g, 9.9 mmol, 1.01 equiv), KOAc (2.88 g, 29.4 mmol, 3 equiv), Pd(dppf)Cl₂·CH₂Cl₂ (240 mg, 0.29 mmol, 0.03 equiv), and 1,4-dioxane (49 mL, 0.2 M). After 18 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 3-8% Et₂O in petroleum ether) to afford the title compound as a white solid (1.2 g, 40%).

ν_{max} (film): 2978, 1708, 1614, 1372, 1298, 1168, 1101 cm⁻¹.


¹H NMR (CDCl₃, 400 MHz): δ 7.79 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 3.64 (s, 3H), 1.63 (q, J = 4.0 Hz, 2H), 1.36 (s, 12H), 1.22 (q, J = 4.0 Hz, 2H).

¹³C NMR (CDCl₃, 126 MHz): δ 174.4, 142.1, 134.2, 129.4, 83.3, 51.9, 28.6, 24.3, 16.2. Carbon bearing boron not observed.

¹¹B NMR (CDCl₃, 128 MHz): δ 31.0.

HRMS: exact mass calculated for [M+H]⁺ (C₁₇H₂₄BO₄) requires m/z 303.1762, found m/z 313.1767.

2-(Benzo[b]thiophen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, **S9**



A mixture of benzo[b]thiophene-2-boronic acid (1.25 g, 7 mmol, 1 equiv), pinacol (830 mg, 7 mmol, 1 equiv), and trifluoroacetic acid (53.7 μ L, 0.7 mmol, 0.1 equiv) in Et₂O (35 mL, 0.2 M) was stirred at room temperature for 2 h under N₂. The mixture was then concentrated under vacuum to give a residue that was diluted with hexane (30 mL), filtered, and concentrated under vacuum to afford the title compound as an off-white solid (1.79 g, 98%).

ν_{max} (film): 2978, 1526, 1348, 1338, 1137 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.91-7.93 (m, 2H), 7.86-7.88 (m, 1H), 7.35-7.40 (m, 2H), 1.40 (s, 12H).


^{13}C NMR (CDCl_3 , 101 MHz): δ 143.8, 140.5, 134.5, 125.3, 124.4, 124.1, 122.5, 84.5, 24.8. Carbon bearing boron not observed.

^{11}B NMR (CDCl_3 , 128 MHz): δ 29.1.

HRMS: exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{14}\text{H}_{18}\text{BO}_2\text{S}$) requires m/z 261.1115, found m/z 261.1115.

4.2 Products from Figure 2 and Scheme 2

[1,1'-Biphenyl]-4-ol, **3a**



Prepared according to General Procedure A using 4-bromophenylboronic acid MIDA ester (70.6 mg, 0.226 mmol, 1 equiv), 4,4,5,5-tetramethyl-2-phenyl-1,3,2-dioxaborolane (69.3 mg, 0.339 mmol, 1.5 equiv), $\text{Pd}(\text{dppf})\text{Cl}_2\cdot\text{DCM}$ (7.4 mg, 0.009 mmol, 4 mol%), K_3PO_4 (144 mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 0.25 M), H_2O (20 μL , 1.13 mmol, 5 equiv) and 30% wt. aq. H_2O_2 (177 μL , 2.26 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (C18 silica gel, 0-60% H_2O in MeCN) to afford the title compound as a white solid (31 mg, 80%).


ν_{max} (solid): 3399, 3098, 3062, 1597, 1485 cm^{-1} .

^1H NMR (CD_3CN , 500 MHz): δ 7.56-7.59 (m, 2H), 7.48-7.51 (m, 2H), 7.42 (t, J = 8.2 Hz, 2H), 7.30 (tt, J = 8.0, 2.0 Hz, 1H), 6.99 (s, 1H), 6.89 (d, J = 8.3 Hz, 2H).

^{13}C NMR ($\text{DMSO}-d_6$, 126 MHz): δ 157.1, 140.2, 130.9, 128.7, 127.7, 126.3, 125.9, 115.8.

HRMS: exact mass calculated for $[\text{M}-\text{H}]^-$ ($\text{C}_{12}\text{H}_9\text{O}$) requires m/z 169.0659, found m/z 169.0658.

3-(Benzo[b]thiophen-2-yl)-5-(trifluoromethyl)phenol, **3b**



Prepared according to General Procedure B using 3-bromo-5-(trifluoromethyl)phenylboronic acid MIDA ester (86 mg, 0.226 mmol, 1 equiv), benzo[b]thiophen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (88.2 mg, 0.339 mmol, 1.5 equiv), Pd(OAc)₂ (2 mg, 0.01 mmol, 4 mol%), SPhos (7.4 mg, 0.02 mmol, 8 mol%), K₃PO₄ (144 mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 0.25 M), H₂O (20 μ L, 1.13 mmol, 5 equiv) and 30% wt. aq. H₂O₂ (177 μ L, 2.26 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 0-30% Et₂O in petroleum ether) to afford the title compound as an orange solid (58 mg, 88%).

ν_{max} (solid): 3305, 3067, 3052, 2923, 1610, 1450, 1439, 1351, 1327 cm⁻¹.


¹H NMR (CD₃CN, 500 MHz): δ 7.93 (d, J = 7.5 Hz, 1H), 7.86 (dd, J = 6.9, 1.6 Hz, 1H), 7.77 (s, 1H), 7.64 (s, 1H), 7.56 (s, 1H), 7.37-7.46 (m, 3H), 7.10 (s, 1H).

¹³C NMR (CD₃CN, 126 MHz): δ 157.9, 141.9, 140.5, 139.4, 136.6, 132.2 (d, ² $J_{\text{C-F}}$ = 32.4 Hz), 132.1 (d, ² $J_{\text{C-F}}$ = 32.4 Hz), 125.2, 125.0, 124.0, 123.9 (d, ¹ $J_{\text{C-F}}$ = 271.8 Hz) 122.3, 121.4, 116.6, 114.3 (d, ³ $J_{\text{C-F}}$ = 3.2 Hz) 111.9 (d, ³ $J_{\text{C-F}}$ = 3.2 Hz).

¹⁹F NMR (CD₃CN, 376 MHz): δ -64.2 (s, 3F).

HRMS: exact mass calculated for [M-H]⁻ (C₁₅H₈F₃OS) requires m/z 293.0253, found m/z 293.0245.

4-(3,5-Dimethylisoxazol-4-yl)phenol, **3c**



Prepared according to General Procedure A using 4-bromophenylboronic acid MIDA ester (70.6 mg, 0.226 mmol, 1 equiv), 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (75.6 mg, 0.339 mmol, 1.5 equiv), Pd(dppf)Cl₂·DCM (7.4 mg, 0.009 mmol, 4 mol%), K₃PO₄ (144 mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 0.25 M), H₂O (20 μ L, 1.13 mmol, 5 equiv), and 30% wt. aq. H₂O₂ (177 μ L, 2.26 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 0-30% Et₂O in petroleum ether) to afford the title compound as a white solid (37 mg, 87%).


ν_{max} (solid): 3194, 3025, 2926, 1612, 1591, 1424 cm⁻¹.

¹H NMR (CD₃CN, 500 MHz): δ 7.18 (d, J = 8.8 Hz, 2H), 7.05 (br. s., 1H), 6.90 (d, J = 8.8 Hz, 2H), 2.35 (s, 3H), 2.20 (s, 3H).

^{13}C NMR (CDCl_3 , 126 MHz): δ 165.0, 158.9, 155.6, 130.4, 122.3, 116.4, 115.8, 11.5, 10.7.

HRMS: exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{11}\text{H}_{12}\text{NO}_2$) requires m/z 190.0863, found m/z 190.0861.

5-(1,5-Dimethyl-1*H*-pyrazol-4-yl)-2-methoxyphenol, **3d**



Prepared according to General Procedure B using 5-bromo-2-methoxyphenylboronic acid MIDA ester (85 mg, 0.25 mmol, 1 equiv), 1,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole (83 mg, 0.375 mmol, 1.5 equiv), $\text{Pd}(\text{OAc})_2$ (2.3 mg, 0.01 mmol, 4 mol%), SPhos (8.2 mg, 0.02 mmol, 8 mol%), K_3PO_4 (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H_2O (22.5 μL , 1.25 mmol, 5 equiv), and 30% wt. aq. H_2O_2 (195 μL , 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 20-70% EtOAc in petroleum ether) to afford the desired product as a white solid (42 mg, 77%).


ν_{max} (film): 3341, 3204, 2920, 2851, 1464, 1034 cm^{-1} .

^1H NMR (CDCl_3 , 400 MHz): δ 7.53 (s, 1H), 6.96 (d, $J = 2.0$ Hz, 1H), 6.91 (d, $J = 8.2$ Hz, 1H), 6.85 (dd, $J = 8.2, 2.0$ Hz, 1H), 3.93 (s, 3H), 3.86 (s, 3H), 2.38 (s, 3H).

^{13}C NMR (CDCl_3 , 101 MHz): δ 145.3, 144.9, 136.4, 134.5, 126.8, 120.1, 118.9, 113.8, 110.6, 55.6, 35.9, 9.8.

HRMS: exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{12}\text{H}_{15}\text{N}_2\text{O}_2$) requires m/z 219.1128, found m/z 219.1126.

3-Fluoro-4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-ol, **3e**



Prepared according to General Procedure A using 4-bromo-2-fluorophenylboronic acid MIDA ester (82.5 mg, 0.25 mmol, 1 equiv), 4,4,5,5-tetramethyl-2-(4-(trifluoromethoxy)phenyl)-1,3,2-dioxaborolane (86 mg, 0.375 mmol, 1.5 equiv), $\text{Pd}(\text{dppf})\text{Cl}_2 \cdot \text{DCM}$ (8.2 mg, 0.01 mmol, 4 mol%), K_3PO_4 (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H_2O (22.5 μL , 1.25 mmol, 5 equiv), and 30% wt. aq. H_2O_2 (195 μL , 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the

purification outlined in the General Procedure (silica gel, 0-10% EtOAc in petroleum ether) to afford the title compound as a white solid (58 mg, 85%).

ν_{\max} (film): 3395, 1503, 1256, 1200, 1159, 1117 cm^{-1} .


^1H NMR (CDCl_3 , 400 MHz): δ 7.50-7.58 (m, 2H), 7.23-7.35 (m, 4H), 7.10 (t, $J = 8.5$ Hz, 1H), 5.23 (br. s., 1H).

^{13}C NMR (CDCl_3 , 101 MHz): δ 151.2 (d, $^1J_{\text{C-F}} = 237.0$ Hz), 148.6, 143.3 (d, $^2J_{\text{C-F}} = 14.6$ Hz), 138.5, 133.1 (d, $^3J_{\text{C-F}} = 5.9$ Hz), 128.0, 123.4 (d, $^3J_{\text{C-F}} = 5.9$ Hz), 121.3, 120.5 (q, $^1J_{\text{C-F}} = 257.5$ Hz), 117.7, 114.2 (d, $^2J_{\text{C-F}} = 20.5$ Hz).

^{19}F NMR (CDCl_3 , 376 MHz): δ -57.8 (s, 3F), -140.4 (s, 1F).

HRMS: exact mass calculated for $[\text{M}]^+$ ($\text{C}_{13}\text{H}_8\text{F}_4\text{O}_2$) requires m/z 272.0455, found m/z 272.0459.

3-(Furan-3-yl)phenol, **3f**



Prepared according to General Procedure A using 3-bromophenylboronic acid MIDA ester (70.6 mg, 0.226 mmol, 1 equiv), 2-(furan-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (65.8 mg, 0.339 mmol, 1.5 equiv), $\text{Pd}(\text{dppf})\text{Cl}_2 \cdot \text{DCM}$ (7.4 mg, 0.009 mmol, 4 mol%), K_3PO_4 (144 mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 0.25 M), H_2O (20 μL , 1.13 mmol, 5 equiv), and 30% wt. aq. H_2O_2 (177 μL , 2.26 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 0-30% Et_2O in petroleum ether) to afford the title compound as a white solid (32 mg, 87%).


ν_{\max} (solid): 3477, 3401, 3150, 3127, 1591, 1513, 1457 cm^{-1} .

^1H NMR (CDCl_3 , 500 MHz): δ 7.72 (s, 1H), 7.47-7.50 (m, 1H), 7.26 (t, $J = 7.9$ Hz, 1H), 7.09 (td, $J = 7.8, 1.1$ Hz, 1H), 6.97-6.99 (m, 1H), 6.72-6.79 (m, 1H), 6.65-6.71 (m, 1H), 4.88 (br. s., 1H).

^{13}C NMR (CDCl_3 , 126 MHz): δ 155.9, 143.7, 138.7, 134.1, 130.1, 126.1, 118.6, 113.9, 112.8, 108.9.

HRMS: exact mass calculated for $[\text{M-H}]^-$ ($\text{C}_{10}\text{H}_7\text{O}_2$) requires m/z 159.0452, found m/z 159.0448.

4'-(Trifluoromethoxy)-[1,1'-biphenyl]-3-ol, **3g**



Prepared according to General Procedure A using 3-bromophenylboronic acid MIDA ester (70.6 mg, 0.226 mmol, 1 equiv), 4,4,5,5-tetramethyl-2-(4-(trifluoromethoxy)phenyl)-1,3,2-dioxaborolane (97.7 mg, 0.339 mmol, 1.5 equiv), Pd(dppf)Cl₂·DCM (7.4 mg, 0.009 mmol, 4 mol%), K₃PO₄ (144 mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 0.25 M), H₂O (20 μL, 1.13 mmol, 5 equiv), and 30% wt. aq. H₂O₂ (177 μL, 2.26 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (C18 silica gel, 0-60% H₂O in MeCN) to afford the title compound as a pale yellow solid (47 mg, 81%).

ν_{max} (solid): 3304, 3047, 2928, 1597, 1485, 1457 cm⁻¹.


¹H NMR (CD₃CN, 500 MHz): δ 7.72-7.68 (m, 2H), 7.37 (d, J = 8.8 Hz, 2H), 7.31 (t, J = 7.9 Hz, 1H), 7.15-7.12 (m, 1H), 7.09-7.07 (m, 2H), 6.89-6.83 (m, 1H).

¹³C NMR (CD₃CN, 126 MHz): δ 157.4, 148.5, 141.0, 140.0, 130.2, 128.6, 121.3, 120.6 (d, $^1J_{\text{C-F}}$ = 255.3 Hz), 118.6, 114.7, 113.8, 29.4.

¹⁹F NMR (CD₃CN, 376 MHz): δ -57.8 (s, 3F).

HRMS: exact mass calculated for [M-H]⁻ (C₁₃H₈F₃O) requires m/z 253.0482, found m/z 253.0482.

Methyl 1-(3'-hydroxy-[1,1'-biphenyl]-4-yl)cyclopropane-1-carboxylate, **3h**



Prepared according to General Procedure A using 3-bromophenylboronic acid MIDA ester (70.6 mg, 0.226 mmol, 1 equiv), methyl 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane-1-carboxylate (102.4 mg, 0.339 mmol, 1.5 equiv), Pd(dppf)Cl₂·DCM (7.4 mg, 0.009 mmol, 4 mol%), K₃PO₄ (144 mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 0.25 M), H₂O (20 μL, 1.13 mmol, 5 equiv), and 30% wt. aq. H₂O₂ (177 μL, 2.26 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 0-30% Et₂O in petroleum ether) to afford the title compound as a white solid (45 mg, 75%).


ν_{\max} (solid): 3440, 3040, 2954, 2926, 2852, 1698, 1590 cm^{-1} .

^1H NMR (CDCl_3 , 500 MHz) δ 7.51 (d, J = 8.5 Hz, 2H), 7.40 (d, J = 8.2 Hz, 2H), 7.27-7.32 (m, 1H), 7.15 (d, J = 7.9 Hz, 1H), 7.01-7.07 (m, 1H), 6.80 (dd, J = 8.0, 2.5 Hz, 1H), 3.66 (s, 3H), 1.63-1.66 (m, 2H), 1.22-1.25 (m, 2H).

^{13}C NMR (CDCl_3 , 126 MHz): δ 175.2, 155.9, 142.6, 139.6, 138.8, 130.9, 129.9, 126.9, 119.7, 114.2, 114.0, 52.5, 28.7, 16.8.

HRMS: exact mass calculated for $[\text{M}-\text{H}]^-$ ($\text{C}_{17}\text{H}_{15}\text{O}_3$) requires m/z 267.1027, found m/z 267.1019.

3-(Thiophen-2-yl)-5-(trifluoromethyl)phenol, **3i**



Prepared according to General Procedure B using 3-bromo-5-(trifluoromethyl)phenylboronic acid MIDA ester (95 mg, 0.25 mmol, 1 equiv), 4,4,5,5-tetramethyl-2-(thiophen-2-yl)-1,3,2-dioxaborolane (79 mg, 0.375 mmol, 1.5 equiv), $\text{Pd}(\text{OAc})_2$ (2.3 mg, 0.01 mmol, 4 mol%), SPhos (8.2 mg, 0.02 mmol, 8 mol%), K_3PO_4 (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H_2O (22.5 μL , 1.25 mmol, 5 equiv), and 30% wt. aq. H_2O_2 (195 μL , 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 0-15% Et_2O in petroleum ether) to afford the title compound as a brown solid (53 mg, 87%).

ν_{\max} (film): 3318, 1599, 1115, 1099 cm^{-1} .


^1H NMR (CDCl_3 , 400 MHz): δ 7.44-7.47 (m, 1H), 7.35-7.39 (m, 2H), 7.26 (t, J = 2.0 Hz, 1H), 7.13 (dd, J = 5.0, 3.5 Hz, 1H), 7.00-7.03 (m, 1H), 5.16 (s, 1H).

^{13}C NMR (CDCl_3 , 101 MHz): δ 156.2, 142.3, 136.9, 132.7 (q, $^2J_{\text{C-F}}$ = 33.1 Hz), 128.2, 126.0, 124.4, 123.7 (q, $^1J_{\text{C-F}}$ = 272.1 Hz), 116.0, 115.3, 111.2.

^{19}F NMR (CDCl_3 , 376 MHz): δ -62.9 (s, 3F).

HRMS: exact mass calculated for $[\text{M}-\text{H}]^-$ ($\text{C}_{11}\text{H}_6\text{F}_3\text{OS}$) requires m/z 243.0097, found m/z 243.0097.

4-(3,5-Dimethylisoxazol-4-yl)-2-fluorophenol, **3j**



Prepared according to General Procedure A using 4-bromo-2-fluorophenylboronic acid MIDA ester (82.5 mg, 0.25 mmol, 1 equiv), 4,4,5,5-tetramethyl-4-(3,5-dimethylisoxazol-4-yl)-1,3,2-dioxaborolane (84 mg, 0.375 mmol, 1.5 equiv), Pd(dppf)Cl₂·DCM (8.2 mg, 0.01 mmol, 4 mol%), K₃PO₄ (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H₂O (22.5 μL, 1.25 mmol, 5 equiv), and 30% wt. aq. H₂O₂ (195 μL, 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 10-20% Et₂O in petroleum ether) to afford the title compound as a white solid (41 mg, 79%).

ν_{max} (film): 3075, 1460, 1410, 1308, 1244, 1213, 1121 cm⁻¹.


¹H NMR (CDCl₃, 400 MHz): δ 7.13-7.08 (m, 1H), 7.00 (dd, J = 11.5, 2.0 Hz, 1H), 6.94 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 5.98 (br. s., 1H), 2.42 (s, 3H), 2.28 (s, 3H).

¹³C NMR (CDCl₃, 101 MHz): δ 164.8, 158.2, 150.6 (d, $^1J_{\text{C-F}}$ = 237.0 Hz), 142.8 (d, $^2J_{\text{C-F}}$ = 16.2 Hz), 125.2 (d, $J_{\text{C-F}}$ = 2.7 Hz), 122.4 (d, $^3J_{\text{C-F}}$ = 8.1 Hz), 117.3 (d, $^3J_{\text{C-F}}$ = 5.4 Hz), 115.9 (d, $^2J_{\text{C-F}}$ = 18.8 Hz), 115.2, 11.0, 10.2.

¹⁹F NMR (CDCl₃, 376 MHz): δ -139.3 (s, 1F).

HRMS: exact mass calculated for [M+H]⁺ (C₁₁H₁₁FNO₂) requires m/z 208.0768, found m/z 208.0768.

4-(Benzo[b]thiophen-2-yl)phenol, **3k**



Prepared according to General Procedure A using 4-bromophenylboronic acid MIDA ester (70.6 mg, 0.226 mmol, 1 equiv), 2-(benzo[b]thiophen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (88.2 mg, 0.339 mmol, 1.5 equiv), Pd(dppf)Cl₂·DCM (7.4 mg, 0.009 mmol, 4 mol%), K₃PO₄ (144 mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 0.25 M), H₂O (20 μL, 1.13 mmol, 5 equiv), and 30% wt. aq. H₂O₂ (177 μL, 2.26 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 0-30% Et₂O in petroleum ether) to afford the title compound as an off-white solid (47 mg, 92%).


ν_{max} (solid): 3388, 3052, 3042, 2923, 1610, 1597, 1507 cm^{-1} .

^1H NMR (DMSO-d_6 , 500 MHz): δ 9.78 (s, 1H), 7.91 (d, $J = 7.9$ Hz, 1H), 7.77 (d, $J = 7.9$ Hz, 1H), 7.63 (s, 1H), 7.57-7.61 (m, 2H), 7.35 (dt, $J = 7.5, 1.3$ Hz, 1H), 7.27-7.31 (m, 1H), 6.86 (d, $J = 8.5$ Hz, 2H).

^{13}C NMR (DMSO-d_6 , 126 MHz): δ 158.5, 144.3, 141.2, 138.5, 128.0, 125.1, 125.0, 124.5, 123.7, 122.7, 118.3, 116.4.

HRMS: exact mass calculated for $[\text{M-H}]^-$ ($\text{C}_{14}\text{H}_9\text{OS}$) requires m/z 225.0380, found m/z 225.0385.

1-(2'-Hydroxy-[1,1'-biphenyl]-4-yl)ethanone, **3l**



Prepared according to General Procedure A using 2-bromophenylboronic acid MIDA ester (92 mg, 0.25 mmol, 1 equiv), 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanone (92 mg, 0.375 mmol, 1.5 equiv), $\text{Pd(dppf)Cl}_2 \cdot \text{DCM}$ (8.2 mg, 0.01 mmol, 4 mol%), K_3PO_4 (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H_2O (22.5 μL , 1.25 mmol, 5 equiv), and 30% wt. aq. H_2O_2 (195 μL , 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 5-20% EtOAc in petroleum ether) to afford the title compound as a white solid (38 mg, 72%).


ν_{max} (film): 3285, 1667, 1479, 1277, 1190, 1179, 1155 cm^{-1} .

^1H NMR (CDCl_3 , 400 MHz): δ 8.11-8.05 (m, 2H), 7.63-7.68 (m, 2H), 7.29-7.34 (m, 2H), 7.08-6.98 (m, 2H), 2.67 (s, 3H).

^{13}C NMR (CDCl_3 , 101 MHz): δ 197.4, 152.0, 142.1, 135.6, 129.9, 129.3, 128.9, 128.5, 126.7, 120.7, 115.8, 26.2.

HRMS: exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{14}\text{H}_{13}\text{O}_2$) requires m/z 213.0910, found m/z 213.0909.

2',4'-Difluoro-[1,1'-biphenyl]-3-ol, **3m**



Prepared according to General Procedure A using 3-bromophenylboronic acid MIDA ester (78 mg, 0.25 mmol, 1 equiv), 2-(2,4-difluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (90 mg, 0.375 mmol, 1.5 equiv), Pd(dppf)Cl₂·DCM (8.2 mg, 0.01 mmol, 4 mol%), K₃PO₄ (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H₂O (22.5 μL, 1.25 mmol, 5 equiv), and 30% wt. aq. H₂O₂ (195 μL, 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 0-10% Et₂O in petroleum ether) to afford the title compound as a white solid (43 mg, 83%).

ν_{\max} (film) 3260, 1597, 1479, 1306, 1265, 1229, 1192, 1140, 1099 cm⁻¹.


¹H NMR (CDCl₃, 400 MHz): δ 7.41 (td, J = 8.8, 6.5 Hz, 1H), 7.34 (t, J = 8.0 Hz, 1H), 7.10 (dq, J = 7.6, 1.5 Hz, 1H), 7.00-7.04 (m, 1H), 6.86-7.00 (m, 3H), 5.06 (s, 1H).

¹³C NMR (CDCl₃, 101 MHz): δ 161.5 (dd, ¹ $J_{\text{C-F}}$ = 250.4 Hz, ³ $J_{\text{C-F}}$ = 5.4), 159.2 (dd, ¹ $J_{\text{C-F}}$ = 250.4 Hz, ³ $J_{\text{C-F}}$ = 5.4), 155.0, 136.1, 130.9 (dd, ³ $J_{\text{C-F}}$ = 6.7, 5.4 Hz), 129.3, 124.4 (dd, ² $J_{\text{C-F}}$ = 18.9 Hz, $J_{\text{C-F}}$ = 5.4 Hz), 121.0, 115.5, 114.3, 111.0 (dd, ² $J_{\text{C-F}}$ = 21.5 Hz, $J_{\text{C-F}}$ = 2.7 Hz), 103.9 (dd, ² $J_{\text{C-F}}$ = 24.2, 26.9 Hz).

¹⁹F NMR (CDCl₃, 376 MHz): δ -111.3 (d, J = 7.5 Hz, 1F), -113.2 (d, J = 7.5 Hz, 1F).

HRMS: exact mass calculated for [M+H]⁺ (C₁₂H₉F₂O) requires m/z 207.0616, found m/z 207.0619.

3-(1-Methyl-1*H*-pyrazol-4-yl)phenol, **3n**



Prepared according to General Procedure A using 3-bromophenylboronic acid MIDA ester (70.6 mg, 0.226 mmol, 1 equiv), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole (71.2 mg, 0.339 mmol, 1.5 equiv), Pd(dppf)Cl₂·DCM (7.4 mg, 0.009 mmol, 4 mol%), K₃PO₄ (144 mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 0.25 M), H₂O (20 μL, 1.13 mmol, 5 equiv), and 30% wt. aq. H₂O₂ (177 μL, 2.26 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 20-80% Et₂O in petroleum ether) to afford the title compound as a yellow solid (33 mg, 83%).


ν_{\max} (solid): 3107, 2926, 2855, 1616, 1569, 1588, 1374 cm⁻¹.

¹H NMR (CD₃CN, 500 MHz): δ 7.79 (s, 1H), 7.72 (s, 1H), 7.19 (t, J = 8.0 Hz, 1H), 7.03 (td, J = 7.6, 1.4 Hz, 1H), 6.98-6.96 (m, 1H), 6.94 (br. s., 1H), 6.74-6.61 (m, 1H), 3.87 (s, 3H).

^{13}C NMR (DMSO- d_6 , 126 MHz): δ 157.7, 135.9, 133.8, 129.7, 127.6, 122.0, 115.9, 113.0, 111.8, 38.6.

HRMS: exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{10}\text{H}_{11}\text{N}_2\text{O}$) requires m/z 175.0866, found m/z 175.0864.

2-Fluoro-4-(furan-3-yl)phenol, **3o**



Prepared according to General Procedure A using 4-bromo-2-fluorophenylboronic acid MIDA ester (83 mg, 0.25 mmol, 1 equiv), 2-(furan-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (73 mg, 0.375 mmol, 1.5 equiv), $\text{Pd}(\text{dppf})\text{Cl}_2 \cdot \text{DCM}$ (8.2 mg, 0.01 mmol, 4 mol%), K_3PO_4 (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H_2O (22.5 μL , 1.25 mmol, 5 equiv), and 30% wt. aq. H_2O_2 (195 μL , 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 0-10% EtOAc in petroleum ether) to afford the title compound as off-white solid (32 mg, 72%).

ν_{max} (film): 3362, 1520, 1497, 1279, 1250, 1231, 1155, 1117, 1086, 1049, 1016 cm^{-1} .


^1H NMR (CDCl_3 , 400 MHz): δ 7.67 (dd, $J = 1.4, 1.0$ Hz, 1H), 7.48 (t, $J = 1.7$ Hz, 1H), 7.22 (dd, $J = 11.5, 2.0$ Hz, 1H), 7.18 (ddd, $J = 8.4, 2.1, 1.0$ Hz, 1H), 7.07-6.99 (m, 1H), 6.64 (dd, $J = 1.8, 0.9$ Hz, 1H), 5.14 (br. s., 1H).

^{13}C NMR (CDCl_3 , 101 MHz): δ 150.7 (d, $^1J_{\text{C-F}} = 237.0$ Hz), 143.3, 141.9 (d, $^2J_{\text{C-F}} = 13.5$ Hz), 137.6, 125.4 (d, $^2J_{\text{C-F}} = 8.1$ Hz), 124.9 (d, $J_{\text{C-F}} = 2.7$ Hz), 121.8 (d, $^3J_{\text{C-F}} = 5.4$ Hz), 117.1, 112.6 (d, $^3J_{\text{C-F}} = 18.8$ Hz), 108.3.

^{19}F NMR (CDCl_3 , 376 MHz): δ -140.7 (s, 1F).

HRMS: exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{10}\text{H}_8\text{FO}_2$) requires m/z 179.0503, found m/z 179.0502.

3-(2,4-Difluorophenyl)-5-(trifluoromethyl)phenol, **3p**



Prepared according to General Procedure B using 3-bromo-5-(trifluoromethyl)phenylboronic acid MIDA ester (95 mg, 0.25 mmol, 1 equiv), 4,4,5,5-tetramethyl-2-(2,4-difluorophenyl)-1,3,2-dioxaborolane (90 mg, 0.375 mmol, 1.5 equiv), Pd(OAc)₂ (2.3 mg, 0.01 mmol, 4 mol%), SPhos (8.2 mg, 0.02 mmol, 8 mol%), K₃PO₄ (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H₂O (22.5 μL, 1.25 mmol, 5 equiv), and 30% wt. aq. H₂O₂ (195 μL, 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 0-20% Et₂O in petroleum ether) to afford the title compound as a brown solid (60 mg, 88%).

ν_{\max} (film): 3331, 1607, 1364, 1271, 1121, 1103 cm⁻¹.


¹H NMR (CDCl₃, 400 MHz): δ 7.43 (td, J = 8.7, 6.3 Hz, 1H), 7.34 (s, 1H), 7.19 (d, J = 1.5 Hz, 1H), 7.14-7.11 (m, 1H), 7.03-6.92 (m, 2H), 5.30 (br. s, 1H).

¹³C NMR (CDCl₃, 101 MHz): δ 162.8 (dd, ¹ $J_{\text{C-F}}$ = 250.0 Hz, ³ $J_{\text{C-F}}$ = 11.0 Hz), 159.7 (dd, ¹ $J_{\text{C-F}}$ = 250.0 Hz, ³ $J_{\text{C-F}}$ = 11.0 Hz), 155.8, 137.4, 132.4 (q, ² $J_{\text{C-F}}$ = 33.1 Hz), 131.4 (dd, ³ $J_{\text{C-F}}$ = 7.5, 7.5 Hz), 123.6 (dd, ² $J_{\text{C-F}}$ = 13.5 Hz, $J_{\text{C-F}}$ = 5.4 Hz), 123.7 (q, ¹ $J_{\text{C-F}}$ = 272.1 Hz), 119.3, 118.2, 111.9 (dd, ² $J_{\text{C-F}}$ = 21.5 Hz, $J_{\text{C-F}}$ = 3.0 Hz), 111.7, 104.6 (dd, ² $J_{\text{C-F}}$ = 25.7, 25.7 Hz).

¹⁹F NMR (CDCl₃, 376 MHz): δ -62.8 (s, 3F), -109.7 (d, J = 8.0 Hz, 1F), -113.1 (d, J = 8.0 Hz, 1F).

HRMS: exact mass calculated for [M+H]⁺ (C₁₃H₈F₅O) requires m/z 275.0490, found m/z 275.0490.

3',4',5'-Trifluoro-3-methoxy-[1,1'-biphenyl]-4-ol, **3q**



Prepared according to General Procedure B using 5-bromo-2-methoxyphenylboronic acid MIDA ester (85 mg, 0.25 mmol, 1 equiv), 4,4,5,5-tetramethyl-2-(3,4,5-trifluorophenyl)-1,3,2-dioxaborolane (97 mg, 0.375 mmol, 1.5 equiv), Pd(OAc)₂ (2.3 mg, 0.01 mmol, 4 mol%), SPhos (8.2 mg, 0.02 mmol, 8 mol%), K₃PO₄ (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H₂O (22.5 μL, 1.25 mmol, 5 equiv), and 30% wt. aq. H₂O₂ (195 μL, 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 5-20% EtOAc in petroleum ether) to afford the title compound as an off-white solid (41 mg, 65%).

ν_{\max} (film): 3530, 2941, 2361, 1503, 1263, 1231, 1211, 1136, 1038, 1022 cm⁻¹.


^1H NMR (CDCl_3 , 400 MHz): δ 7.17-7.12 (m, 2H), 7.10 (d, $J = 2.5$ Hz, 1H), 7.01 (dd, $J = 8.1, 2.5$ Hz, 1H), 6.93 (d, $J = 8.1$ Hz, 1H), 5.73 (br. s., 1H), 3.96 (s, 3H).

^{13}C NMR (CDCl_3 , 101 MHz): δ 151.5 (ddd, $^1J_{\text{C-F}} = 248.9$ Hz, $^2J_{\text{C-F}} = 10.0$ Hz, $^3J_{\text{C-F}} = 4.1$ Hz), 147.1, 146.2, 139.0 (dt, $^1J_{\text{C-F}} = 251.1$ Hz, $^2J_{\text{C-F}} = 15.6$ Hz), 137.1 (td, $^3J_{\text{C-F}} = 8.0$ Hz, $J_{\text{C-F}} = 4.3$ Hz), 131.8, 118.7, 113.2, 111.1, 110.7 (dd, $^2J_{\text{C-F}} = 15.8$ Hz, $^3J_{\text{C-F}} = 6.0$ Hz), 56.2.

^{19}F NMR (CDCl_3 , 376 MHz): δ -134.5 (d, $J = 20.4$ Hz, 2F), -163.6 (t, $J = 20.4$ Hz, 1F).

HRMS: exact mass calculated for $[\text{M-H}]^-$ ($\text{C}_{13}\text{H}_8\text{F}_3\text{O}_2$) requires m/z 253.0482, found m/z 253.0477.

2-(1-Methyl-1*H*-pyrazol-4-yl)phenol, **3r**



Prepared according to General Procedure A using 2-bromophenylboronic acid MIDA ester (70.6 mg, 0.226 mmol, 1 equiv), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole (71.2 mg, 0.339 mmol, 1.5 equiv), $\text{Pd}(\text{dppf})\text{Cl}_2 \cdot \text{DCM}$ (7.4 mg, 0.009 mmol, 4 mol%), K_3PO_4 (144 mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 0.25 M), H_2O (20 μL , 1.13 mmol, 5 equiv), and 30% wt. aq. H_2O_2 (177 μL , 2.26 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 20-80% Et_2O in petroleum ether) to afford the title compound as a yellow solid (30 mg, 75%).


ν_{max} (solid): 3060, 2928, 2852, 1566, 1457, 1355 cm^{-1} .

^1H NMR (CD_3CN , 500 MHz): δ 7.96 (s, 1H), 7.82 (s, 1H), 7.51 (dd, $J = 7.7, 1.7$ Hz, 1H), 7.20 (s, 1H), 7.05-7.11 (m, 1H), 6.87-6.93 (m, 2H), 3.89 (s, 3H).

^{13}C NMR (CD_3CN , 126 MHz): δ 153.0, 137.3, 129.4, 127.4, 127.0, 120.2, 119.8, 118.3, 115.8, 38.3.

HRMS: exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{10}\text{H}_{11}\text{N}_2\text{O}$) requires m/z 175.0866, found m/z 175.0864.

5-(3,6-Dihydro-2*H*-pyran-4-yl)-2-methoxyphenol, **3s**



Prepared according to General Procedure B using (5-bromo-2-methoxyphenyl)boronic acid MIDA ester (85 mg, 0.25 mmol, 1 equiv), 2-(3,6-dihydro-2*H*-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (79 mg, 0.375 mmol, 1.5 equiv), Pd(OAc)₂ (2.3 mg, 0.01 mmol, 4 mol%), SPhos (8.2 mg, 0.02 mmol, 8 mol%), K₃PO₄ (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H₂O (22.5 μL, 1.25 mmol, 5 equiv), and 30% wt. aq. H₂O₂ (195 μL, 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 10-20% EtOAc in petroleum ether) to afford the title compound as an off-white solid (35 mg, 67%).


ν_{max} (film): 3302, 2916, 1510, 1276, 1118, 1028, 1014 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.00 (d, *J* = 2.2 Hz, 1H), 6.89 (dd, *J* = 8.4, 2.2 Hz, 1H), 6.82 (d, *J* = 8.4 Hz, 1H), 6.03 (tt, *J* = 3.0, 1.5 Hz, 1H), 5.60 (br. s, 1H), 4.31 (q, *J* = 2.8 Hz, 2H), 3.92 (t, *J* = 5.5 Hz, 2H), 3.89 (s, 3H), 2.45-2.50 (m, 2H).

¹³C NMR (CDCl₃, 101 MHz): δ 145.5, 145.0, 133.5, 132.9, 120.6, 115.9, 110.6, 109.9, 65.4, 64.0, 55.5, 26.7.

HRMS: exact mass calculated for [M+H]⁺ (C₁₂H₁₅O₃) requires *m/z* 207.1016, found *m/z* 207.1012.

3-Fluoro-2',3',4',5'-tetrahydro-[1,1'-biphenyl]-4-ol, **3t**



Prepared according to General Procedure A using 4-bromo-2-fluorophenylboronic acid MIDA ester (82.5 mg, 0.25 mmol, 1 equiv), 2-(cyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (78 mg, 0.375 mmol, 1.5 equiv), Pd(dppf)Cl₂·DCM (8.2 mg, 0.01 mmol, 4 mol%), K₃PO₄ (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H₂O (22.5 μL, 1.25 mmol, 5 equiv), and 30% wt. aq. H₂O₂ (195 μL, 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 0-10% EtOAc in petroleum ether) to afford the title compound as an off-white solid (36 mg, 75%).

ν_{max} (film): 3314, 2928, 2859, 2359, 1593, 1516, 1431, 1290, 1267 cm⁻¹.


¹H NMR (CDCl₃, 400 MHz): δ 7.13 (dd, *J* = 12.5, 2.0 Hz, 1H), 7.08 (ddd, *J* = 8.0, 2.0, 1.0 Hz, 1H), 6.99-6.89 (m, 1H), 6.10-6.04 (m, 1H), 5.18 (d, *J* = 3.5 Hz, 1H), 2.41-2.30 (m, 2H), 2.27-2.13 (m, 2H), 1.84-1.72 (m, 2H), 1.71-1.60 (m, 2H).

^{13}C NMR (CDCl_3 , 101 MHz): δ 150.4 (d, $^1J_{\text{C-F}} = 237.0$ Hz), 141.5 (d, $^2J_{\text{C-F}} = 16.2$ Hz), 135.7 (d, $^3J_{\text{C-F}} = 8.1$ Hz), 134.6 (d, $J_{\text{C-F}} = 2.7$ Hz), 123.7, 120.6 (d, $^3J_{\text{C-F}} = 5.4$ Hz), 116.2, 111.5 (d, $^2J_{\text{C-F}} = 18.8$ Hz), 26.9, 25.3, 22.5, 21.6.

^{19}F NMR (CDCl_3 , 376 MHz): δ -141.4 (s, 1F).

HRMS: exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{12}\text{H}_{14}\text{FO}$) requires m/z 193.1023, found m/z 193.1023.

(*E*)-3-(2-Cyclopropylvinyl)phenol, **3u**



Prepared according to General Procedure B using 3-bromophenylboronic acid MIDA ester (78 mg, 0.25 mmol, 1 equiv), (*E*)-2-(2-cyclopropylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (73 mg, 0.375 mmol, 1.5 equiv), $\text{Pd}(\text{OAc})_2$ (2.3 mg, 0.01 mmol, 4 mol%), SPhos (8.2 mg, 0.02 mmol, 8 mol%), K_3PO_4 (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H_2O (22.5 μL , 1.25 mmol, 5 equiv), and 30% wt. aq. H_2O_2 (195 μL , 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 0-15% EtOAc in petroleum ether) to afford the title compound as an off-white solid (29 mg, 72%).


ν_{max} (film): 3321, 3005, 2359, 1649, 1607, 1580, 1491, 1449, 1277, 1252, 1229, 1153 cm^{-1} .

^1H NMR (CDCl_3 , 400 MHz): δ 7.17 (t, $J = 8.0$ Hz, 1H), 6.94-6.88 (m, 1H), 6.77-6.84 (m, 1H), 6.68 (ddd, $J = 8.0, 2.5, 1.0$ Hz, 1H), 6.43 (d, $J = 15.7$ Hz, 1H), 5.73 (dd, $J = 15.7, 8.8$ Hz, 1H), 4.99 (s, 1H), 1.64-1.52 (m, 1H), 0.89-0.81 (m, 2H), 0.57-0.49 (m, 2H).

^{13}C NMR (CDCl_3 , 101 MHz): δ 155.2, 139.1, 135.1, 129.2, 126.5, 118.0, 113.1, 111.7, 14.0, 6.8.

HRMS: exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{11}\text{H}_{13}\text{O}$) requires m/z 161.0959, found m/z 161.0959.

(*E*)-2-Styrylphenol, **3v**



Prepared according to General Procedure A using 2-bromophenylboronic acid MIDA ester (70.6 mg, 0.226 mmol, 1 equiv), (*E*)-4,4,5,5-tetramethyl-2-styryl-1,3,2-dioxaborolane (78.0 mg, 0.339 mmol, 1.5 equiv), Pd(dppf)Cl₂·DCM (7.4 mg, 0.009 mmol, 4 mol%), K₃PO₄ (144 mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 0.25 M), H₂O (20 μL, 1.13 mmol, 5 equiv), and 30% wt. aq. H₂O₂ (177 μL, 2.26 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 0-30% Et₂O in petroleum ether) to afford the title compound as a yellow solid (38 mg, 85%).


ν_{max} (solid): 3526, 3042, 2927, 1584, 1497, 1454, 1329 cm⁻¹.

¹H NMR (CDCl₃, 500 MHz): δ 7.52-7.57 (m, 3H), 7.35-7.41 (m, 3H), 7.28 (s, 1H), 7.11-7.19 (m, 2H), 6.97 (dt, *J* = 7.5, 0.8 Hz, 1H), 6.82 (dd, *J* = 8.2, 0.9 Hz, 1H), 4.97 (br. s., 1H).

¹³C NMR (CDCl₃, 126 MHz): δ 153.0, 137.6, 130.2, 128.7, 127.7, 127.3, 126.6, 124.7, 123.0, 121.2, 116.0.

HRMS: exact mass calculated for [M-H]⁻ (C₁₄H₁₁O) requires *m/z* 195.0815, found *m/z* 195.0821.

4-(3,6-Dihydro-2*H*-pyran-4-yl)phenol, **3w**



Prepared according to General Procedure A using 4-bromophenylboronic acid MIDA ester (70.6 mg, 0.226 mmol, 1 equiv), 2-(3,6-dihydro-2*H*-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (71.2 mg, 0.339 mmol, 1.5 equiv), Pd(dppf)Cl₂·DCM (7.4 mg, 0.009 mmol, 4 mol%), K₃PO₄ (144 mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 0.25 M), H₂O (20 μL, 1.13 mmol, 5 equiv), and 30% wt. aq. H₂O₂ (177 μL, 2.26 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 0-30% Et₂O in petroleum ether) to afford the title compound as a white solid (48 mg, 93%).


ν_{max} (solid): 3271, 2924, 2872, 1610, 1588, 1515, 1442 cm⁻¹.

¹H NMR (CD₃CN, 500 MHz): δ 7.30 (d, *J* = 8.8 Hz, 2H), 6.91 (br. s., 1H), 6.79 (d, *J* = 8.8 Hz, 2H), 6.06 (tt, *J* = 2.9, 1.5 Hz, 1H), 4.23 (q, *J* = 2.8 Hz, 2H), 3.86 (t, *J* = 5.5 Hz, 2H), 2.47-2.42 (m, 2H).

¹³C NMR (CD₃CN, 126 MHz): δ 156.3, 133.3, 132.1, 125.8, 120.4, 115.1, 65.4, 64.0, 26.9.

HRMS: exact mass calculated for $[M+H]^+$ ($C_{11}H_{13}O_2$) requires m/z 177.0910, found m/z 177.0906.

2',4'-Difluoro-4-hydroxy-[1,1'-biphenyl]-3-carboxylic acid (Diflunisal), **7**



To a solution of methyl 2',4'-difluoro-4-hydroxy-[1,1'-biphenyl]-3-carboxylate (13 mg, 0.049 mmol, 1 equiv) in THF (1 mL) and water (1 mL) was added KOH (3 mg, 0.054 mmol, 1.1 equiv). The reaction was heated to 80 °C for 3 h before being allowed to cool to room temperature and concentrated under vacuum. The residue was partitioned between EtOAc (10 mL) and 2 M HCl (5 mL) and the aqueous extracted with EtOAc (2x10 mL). The combined organics were dried through a hydrophobic frit and evaporated to dryness to afford the desired product (12 mg, 98%) as a white solid.

ν_{\max} (film): 2961, 2614, 1668, 1618, 1587, 1483, 1449, 1300, 1267, 1236, 1209 cm^{-1} .


^1H NMR (DMSO- d_6 , 400 MHz): δ 7.94-7.91 (m, 1H), 7.70-7.67 (m, 1H), 7.59 (td, J = 8.9, 6.6 Hz, 1H), 7.35 (ddd, J = 11.4, 9.1, 2.5 Hz, 1H), 7.21-7.16 (m, 1H), 7.08 (d, J = 8.5 Hz, 1H). Exchangeable protons were not observed.

^{13}C NMR (DMSO- d_6 , 101 MHz): δ 171.5, 160.7, 160.1, 161.5 (dd, $^1J_{\text{C-F}}$ = 250.0 Hz, $^3J_{\text{C-F}}$ = 11.0 Hz), 159.0 (dd, $^1J_{\text{C-F}}$ = 250.0 Hz, $^3J_{\text{C-F}}$ = 11.0 Hz), 135.8, 131.5 (dd, $^3J_{\text{C-F}}$ = 5.4 Hz, $^3J_{\text{C-F}}$ = 8.8 Hz), 130.3, 125.1, 123.7 (dd, $^2J_{\text{C-F}}$ = 17.6 Hz, $J_{\text{C-F}}$ = 2.7 Hz), 117.6, 113.2, 112.0 (dd, $^2J_{\text{C-F}}$ = 20.5 Hz, $J_{\text{C-F}}$ = 2.7 Hz), 104.5 (dd, $^2J_{\text{C-F}}$ = 26.5, 26.5 Hz).

^{19}F NMR (DMSO- d_6 , 376 MHz): δ -111.40 (d, J = 8.2 Hz, 1F), -114.17 (d, J = 8.2 Hz, 1F).

HRMS: exact mass calculated for $[M-H]^-$ ($C_{13}H_7F_2O_3$) requires m/z 249.0369, found m/z 249.0370.

4'-Hydroxy-[1,1'-biphenyl]-4-carbonitrile, **8**



Prepared according to General Procedure A using 4-bromophenylboronic acid MIDA ester (78 mg, 0.25 mmol, 1 equiv), 2-(4-cyanophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (86 mg, 0.375 mmol, 1.5 equiv), Pd(dppf)Cl $_2$ ·DCM (8.2 mg, 0.01 mmol, 4 mol%), K $_3$ PO $_4$ (159 mg, 0.75 mmol, 3

equiv), THF (1 mL, 0.25 M), H₂O (22.5 μ L, 1.25 mmol, 5 equiv), and 30% wt. aq. H₂O₂ (195 μ L, 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was subjected to the purification outlined in the General Procedure (silica gel, 0-15% Et₂O in petroleum ether) to afford the desired product as a white solid (39 mg, 80%).


ν_{max} (film): 3375, 2228, 1601, 1587, 1491, 1204, 1179 cm⁻¹.

¹H NMR (DMSO-d₆, 400 MHz) δ 9.79 (s, 1H), 7.85 (d, J = 8.5 Hz, 2H), 7.82 (dd, J = 22.4, 8.7 Hz, 4H), 6.89 (d, J = 8.5 Hz, 2H).

¹³C NMR (DMSO-d₆, 101 MHz): δ 158.3, 144.6, 132.7, 128.8, 128.3, 126.5, 119.1, 116.0, 108.7.

HRMS: exact mass calculated for [M-H]⁻ (C₁₃H₈NO) requires m/z 194.0611, found m/z 194.0606.

4-Methoxy-4'-(thiophen-2-yl)-[1,1'-biphenyl]-3-ol, **9**



To an oven dried 5 mL microwave vial was added 4-bromophenylboronic acid MIDA ester (78 mg, 0.25 mmol, 1 equiv), 4,4,5,5-tetramethyl-2-(thiophen-2-yl)-1,3,2-dioxaborolane (79 mg, 0.375 mmol, 1.5 equiv), Pd(dppf)Cl₂·DCM (8.2 mg, 0.01 mmol, 4 mol%), and K₃PO₄ (159 mg, 1 mmol, 4 equiv). The vial was then capped and purged with N₂ before addition of THF (1 mL, 0.25 M) and H₂O (90 μ L, 5 mmol, 20 equiv). The reaction mixture was then heated to 90 °C in a sand bath for 24 h. The reaction mixture was allowed to cool to room temperature before adding (5-bromo-2-methoxyphenyl)boronic acid MIDA ester (85 mg, 0.25 mmol, 1 equiv). The vial was then recapped and purged again with N₂ before being heated to 90 °C for a further 24 h. The reaction mixture was allowed to cool to room temperature then decapped, cooled to 0 °C and 30% wt. aq. H₂O₂ (195 μ L, 2.5 mmol, 10 equiv) was added dropwise. The reaction mixture was then stirred at room temperature for 3 h. The reaction mixture was then cooled to 0 °C and quenched with sodium metabisulphite (190 mg, 1 mmol, 4 equiv) before being concentrated under vacuum. The residue was then dissolved in EtOAc (10 mL) and washed with sat. aq. NH₄Cl (2x10 mL) and brine (10 mL). The aqueous extracts were extracted with EtOAc (10 mL), the combined organics filtered through a hydrophobic frit packed with Celite® and concentrated under vacuum before being purified by column chromatography (silica gel, 10-20% Et₂O in petroleum ether) to afford the title compound as an off-white solid (64 mg, 91%).

ν_{max} (film): 3377, 2980, 1502, 1263, 1219 cm^{-1} .

^1H NMR (CDCl_3 , 500 MHz): δ 7.55-7.49 (m, 2H), 7.23 (ddd, $J = 4.8, 4.3, 1.1$ Hz, 2H), 7.10-7.06 (m, 2H), 6.99 (dd, $J = 8.6, 2.4$ Hz, 1H), 6.89-6.85 (m, 2H), 6.74 (d, $J = 8.6$ Hz, 1H), 5.65 (br. s., 1H), 3.90 (s, 3H).

^{13}C NMR (CDCl_3 , 126 MHz): δ 154.6, 146.0, 145.4, 143.7, 127.4, 127.1, 127.0, 123.4, 122.3, 121.6, 117.4, 115.3, 112.8, 111.4, 55.6


HRMS: exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{17}\text{H}_{15}\text{O}_2\text{S}$) requires m/z 283.0787, found m/z 283.0788.

5. References


1. W. L. F. Armarego and C. Chai, *Purification of Laboratory Chemicals*, 7th ed., Elsevier, Oxford, 2013.

6. NMR and HRMS spectra for intermediates and products


^1H NMR of S1, DMSO- d_6 , 400 MHz



^{13}C NMR of S1, DMSO- d_6 , 101 MHz



¹⁹F NMR of S1, DMSO-d₆, 376 MHz




HRMS of S1


JF90-1 MW=379?
(MeCN)/MeCN
C₁₂H₁₀BBrF₃NO₄

EPSRC National Facility Swansea
LTQ Orbitrap XL


James Fyfe
19/06/2014 16:49:38



^1H NMR of S2, CDCl_3 , 400 MHz



^{13}C NMR of S2, CDCl_3 , 101 MHz




HRMS of S2

RL83 MW=296?
C₁₄H₁₈BClO₄
(MeOH)/MeOH + NH₄OAc

EPSRC National Facility Swansea
LTQ Orbitrap XL



James Fyfe
11/09/2014 12:22:52




NL:
7.69E7
STRWAT332-OE-HNESP-2#4-
27 RT: 0.10-0.72 AV: 24 T:
FTMS + p NSI Full ms
[150.00-2000.00]

NL:
1.21E4
C₁₄H₁₈BClO₄H:
C₁₄H₁₉B₁Cl₁O₄
p (gss, s /p:40) Chrg 1
R: 100000 Res .Pwr . @FWHM


¹H NMR of S3, DMSO-d₆, 400 MHz



^{13}C NMR of S3, DMSO- d_6 , 101 MHz



^{19}F NMR of S3, DMSO- d_6 , 376 MHz




HRMS of S3

RL89 MW=276?
C₈H₆BClF₃KO₂
(MeOH)MeOH

EPSRC National Facility Swansea
LTQ Orbitrap XL


James Fyfe
10/09/2014 14:58:39




NL:
3.71E6
STRWAT331-OE-HNESN#2-
16 RT: 0.04-0.42 AV: 15 T:
FTMS - p NSI Full ms
[150.00-2000.00]

NL:
1.30E4
C₈H₆BClF₃O₂
C₈H₆B₁Cl₁F₃O₂
p (gss, s /p:40) Chrg -1
R: 100000 Res .Pwr . @FWHM


¹H NMR of S4, DMSO-d₆, 400 MHz



¹H NMR of S5, DMSO-d₆, 400 MHz



¹³C NMR of S5, DMSO-d₆, 101 MHz




HRMS of S5

RL92 MW=325?
(MeOH)/MeOH + NH₄OAc
C₁₃H₁₃BCINO₆

EPSRC National Facility Swansea
LTQ Orbitrap XL


James Fyfe
11/09/2014 10:43:17




NL:
6.11E6
STRWAT330-OA-HNESP#9-
23 RT: 0.15-0.54 AV: 15 T:
FTMS + p NSI Full ms
[140.00-1935.00]

NL:
1.21E4
C₁₃H₁₃BCINO₆H:
C₁₃H₁₄B₁Cl₁N₁O₆
p (gss, s /p:40) Chrg 1
R: 90000 Res .Pwr . @FWHM


¹H NMR of S6, CDCl₃, 400 MHz



^{13}C NMR of S6, CDCl_3 , 101 MHz



^{19}F NMR of S6, CDCl_3 , 376 MHz




HRMS of S6

RL84 MW=264?
C₁₄H₁₀F₂O₃
(MeOH)/MeOH

EPSRC National Facility Swansea
LTQ Orbitrap XL


James Fyfe
10/09/2014 15:33:23




NL:
5.03E6
STRWAT329-OE-HNESN-2#2-
19 RT: 0.03-0.50 AV: 18 T:
FTMS - p NSI Full ms
[150.00-2000.00]

NL:
2.00E4
C₁₄H₉F₂O₃⁺
C₁₄H₉F₂O₃⁺
p (gss, s /p:40) Chrg -1
R: 100000 Res .Pwr . @FWHM


¹H NMR of S7, DMSO-d₆, 400 MHz



^{13}C NMR of S7, DMSO- d_6 , 101 MHz



^{19}F NMR of S7, DMSO- d_6 , 376 MHz




HRMS of S7


JF77-2 MW=329?
ASAP(SOLID)

EPSRC UK National Facility Swansea
LTQ Orbitrap XL


James
24/06/2014 16:02:41



¹H NMR of S8, CDCl₃, 400 MHz



¹³C NMR of S8, CDCl₃, 101 MHz




HRMS of S8

CS21-A1 MW=302?
C₁₇H₂₃BO₄
(MeOH)/MeOH + NH₄OAc

EPSRC National Facility Swansea
LTQ Orbitrap XL


James Fyfe
03/02/2014 11:41:47




NL:
6.08E7
STRWAT168-OA-HNESP#29-
48 RT: 0.66-1.14 AV: 19 T:
FTMS + p NSI Full ms
[120.00-2000.00]

NL:
1.55E4
C₁₇ H₂₃ BO₄ H:
C₁₇ H₂₄ B₁ O₄
p (gss, s /p:40) Chrg 1
R: 100000 Res .Pwr . @FWHM

^1H NMR of S9, CDCl_3 , 400 MHz



^{13}C NMR of S9, CDCl_3 , 101 MHz




HRMS of S9


JM18 MW=260?
ASAP (SOLID)

EPSRC National Centre Swansea
LTQ Orbitrap XL


Fyfe
11/03/2014 15:25:33



¹H NMR of 3a, CD₃CN, 500 MHz



¹³C NMR of 3a, DMSO-d₆, 126 MHz




HRMS of 3a

JM29 MW=170?
(MeCN)/MeCN
C₁₂H₁₀O

EPSRC National Facility Swansea
LTQ Orbitrap XL

Diana Castagna
06/03/2014 07:48:03


SM: 7G




NL:
4.46E7
STRWAT189-OA-HNESN-2#1-
5 RT: 0.20-0.43 AV: 4 T:
FTMS - p NSI Full ms
[120.00-2000.00]

NL:
2.06E4
C₁₂H₉O:
C₁₂H₉O₁
p (gss, s /p:40) Chrg -1
R: 100000 Res .Pwr . @FWHM


^1H NMR of 3b, CD_3CN , 500 MHz



^{13}C NMR of 3b, CD_3CN , 126 MHz



¹⁹F NMR of 3b, CD₃CN, 376 MHz




HRMS of 3b

JM46 MW=294?
(MeOH)/MeOH

EPSRC National Facility Swansea
LTQ Orbitrap XL


James Fyfe
17/03/2014 13:33:44




NL:
1.89E7
STRWAT209-OE-HNESN-
2#38 RT: 1.12 AV: 1 T: FTMS
- p NSI Full ms [133.00-798.00]

NL:
1.89E4
C₁₅H₈F₃OS:
C₁₅H₈F₃O₁S₁
p (gss, s /p:40) Chrg -1
R: 100000 Res .Pwr . @FWHM

^1H NMR of 3c, CD_3CN , 500 MHz



^{13}C NMR of 3c, CDCl_3 , 126 MHz




HRMS of 3c


JM38 MW=189?
C₁₁H₁₁NO₂
(DCM)/MeOH + NH₄OAc
SM: 7G

EPSRC National Facility Swansea
LTQ Orbitrap XL


Diana Castagna
27/02/2014 11:49:09



¹H NMR of 3d, CDCl₃, 400 MHz



¹³C NMR of 3d, CDCl₃, 101 MHz




HRMS of 3d

RL53 MW=218?
C₁₂H₁₄N₂O₂
(DCM)/MeOH + NH₄OAc
SM: 7G

EPSRC National Facility Swansea
LTQ Orbitrap XL


James Fyfe
15/05/2014 09:49:44




NL:
2.29E7
STRWAT249-OC-HNESP#10-
22 RT: 0.17-0.51 AV: 13 T:
FTMS + p NSI Full ms
[120.00-2000.00]

NL:
2.03E4
C₁₂H₁₄N₂O₂H:
C₁₂H₁₅N₂O₂
p (gss, s /p:40) Chrg 1
R: 100000 Res .Pwr . @FWHM


^1H NMR of 3e, CDCl_3 , 400 MHz



^{13}C NMR of 3e, CDCl_3 , 101 MHz



¹⁹F NMR of 3e, CDCl₃, 376 MHz




HRMS of 3e


RL55 MW=272?
ASAP(SOLID)

EPSRC UK National Facility Swansea
LTQ Orbitrap XL


Fyle
29/05/2014 07:53:47



^1H NMR of 3f, CDCl_3 , 500 MHz



^{13}C NMR of 3f, CDCl_3 , 126 MHz




HRMS of 3f

JM40 MW=160?
(MeCN)/MeOH
SM: 7G

EPSRC National Facility Swansea
LTQ Orbitrap XL


James Fyfe
13/03/2014 13:51:56




NL:
3.51E7
STRWAT216-OA-HNESN#4
RT: 0.43 AV: 1 T: FTMS - p
NSI Full ms [120.00-2000.00]

NL:
2.10E4
C₁₀H₇O₂:
C₁₀H₇O₂
p (gss, s /p:40) Chrg -1
R: 100000 Res .Pwr . @FWHM


¹H NMR of 3g, CD₃CN, 500 MHz



^{13}C NMR of 3g, CD_3CN , 126 MHz



^{19}F NMR of 3g, CD_3CN , 376 MHz




HRMS of 3g

JM30 MW=254?
C₁₃H₉F₃O₂
(MeCN)/MeOH

EPSRC National Facility Swansea
LTQ Orbitrap XL


Diana Castagna
28/02/2014 07:42:58




NL:
4.89E7
STRWAT188-OA-HNESN#2-6
RT: 0.26-0.60 AV: 5 T: FTMS -
p NSI Full ms [120.00-2000.00]

NL:
2.03E4
C₁₃ H₉ F₃ O₂:
C₁₃ H₉ F₃ O₂:
p (gss, s /p:40) Chrg -1
R: 100000 Res .Pwr . @FWHM

¹H NMR of 3h, CDCl₃, 500 MHz



^{13}C NMR of 3h, CDCl_3 , 126 MHz




HRMS of 3h

JM45 MW=268?
(MeOH)/MeOH
SM: 7G

EPSRC National Facility Swansea
LTQ Orbitrap XL


James Fyfe
13/03/2014 13:49:00




NL:
3.14E7
STRWAT211-OA-HNESN#4
RT: 0.43 AV: 1 T: FTMS - p
NSI Full ms [120.00-2000.00]

NL:
1.94E4
 $\text{C}_{17}\text{H}_{15}\text{O}_3$:
 $\text{C}_{17}\text{H}_{15}\text{O}_3$
p (gss, s/p:40) Chrg -1
R: 100000 Res .Pwr . @FWHM


¹H NMR of 3i, CDCl₃, 400 MHz



¹³C NMR of 3i, CDCl₃, 101 MHz



¹⁹F NMR of 3i, CDCl₃, 376 MHz




HRMS of 3i

RL74 MW=244?
C₁₁H₇F₃OS
(MeOH)/MeOH

EPSRC National Facility Swansea
LTQ Orbitrap XL


James Fyfe
10/09/2014 15:14:39




NL:
1.36E6
STRWAT334-OE-HNESN#15-
25 RT: 0.39-0.67 AV: 11 T:
FTMS - p NSI Full ms
[150.00-2000.00]

NL:
1.97E4
C₁₁H₆F₃OS:
C₁₁H₆F₃O₁S₁
p (gss, s /p:40) Chrg -1
R: 100000 Res .Pwr . @FWHM


¹H NMR of 3j, CDCl₃, 400 MHz




¹³C NMR of 3j, CDCl₃, 101 MHz




¹⁹F NMR of 3j, CDCl₃, 376 MHz




HRMS of 3j



¹H NMR of 3k, DMSO-d₆, 500 MHz



¹³C NMR of 3k, DMSO-d₆, 126 MHz




HRMS of 3k


JM20 MW=226?
C₁₄H₁₀O₃
(MeCN)/MeOH

EPSRC National Facility Swansea
LTQ Orbitrap XL


Diana Castagna
28/02/2014 07:49:14



¹H NMR of 3l, CDCl₃, 400 MHz



¹³C NMR of 3l, CDCl₃, 101 MHz




HRMS of 3l


RL46 MWT=212?
ASAP(SOLID)

EPSRC UK National Facility Swansea
LTQ Orbitrap XL


James Fyfe
15/05/2014 10:04:28




^1H NMR of 3m, CDCl_3 , 400 MHz




^{13}C NMR of 3m, CDCl_3 , 101 MHz




¹⁹F NMR of 3m, CDCl₃, 376 MHz




HRMS of 3m



^1H NMR of 3n, CD_3CN , 500 MHz



^{13}C NMR of 3n, DMSO-d_6 , 126 MHz




HRMS of 3n


JM32 MW=174?
C₁₀H₁₀N₂O
(DCM)/MeOH + NH₄OAc
SM: 7G

EPSRC National Facility Swansea
LTQ Orbitrap XL


Diana Castagna
27/02/2014 11:52:08




¹H NMR of 3o, CDCl₃, 400 MHz



^{13}C NMR of 3o, CDCl_3 , 101 MHz



^{19}F NMR of 3o, CDCl_3 , 376 MHz




HRMS of 3o


RL15 MW=178?
ASAP(SOLID)

EPSRC UK National Facility Swansea
LTQ Orbitrap XL


Fyfe
28/05/2014 08:05:18




¹H NMR of 3p, CDCl₃, 400MHz



^{13}C NMR of 3p, CDCl_3 , 101 MHz



^{19}F NMR of 3p, CDCl_3 , 376 MHz




HRMS of 3p


RL77 MW=274?
ASAP(SOLID)

EPSRC UK National Facility Swansea
LTQ Orbitrap XL


Fyfe
29/05/2014 07:39:23




1H NMR of 3q, $CDCl_3$, 400 MHz



^{13}C NMR of 3q, CDCl_3 , 101 MHz



^{19}F NMR of 3q CDCl_3 , 376 MHz




HRMS of 3q

RL19 MW=254?
C₁₃H₉F₃O₂
(MeOH)/MeOH
SM: 7G

EPSRC National Facility Swansea
LTQ Orbitrap XL


James Fyfe
10/09/2014 15:29:21




NL:
3.41E6
STRWAT333-OE-HNESN-2#1-
12 RT: 0.00-0.31 AV: 12 T:
FTMS - p NSI Full ms
[150.00-2000.00]

NL:
2.03E4
C₁₃H₈F₃O₂⁺
C₁₃H₈F₃O₂⁺
p (gss, s /p:40) Chrg -1
R: 100000 Res .Pwr . @FWHM

¹H NMR of 3r, CD₃CN, 500 MHz



¹³C NMR of 3r, CD₃CN, 126 MHz




HRMS of 3r


JM43 MW=174?
ASAP (SOLID)

EPSRC National Centre Swansea
LTQ Orbitrap XL


Fyle
11/03/2014 14:20:07



^1H NMR of 3s, CDCl_3 , 400 MHz



^{13}C NMR of 3s, CDCl_3 , 101 MHz




HRMS of 3s


RL62-1 MW=206?
ASAP(dcm)

EPSRC National Centre Swansea
LTQ Orbitrap XL


Jamie
24/09/2014 07:58:53




¹H NMR of 3t, CDCl₃, 400 MHz



^{13}C NMR of 3t, CDCl_3 , 101 MHz



^{19}F NMR of 3t, CDCl_3 , 376 MHz




HRMS of 3t


RL20 MWT=212?
ASAP(SOLID)

EPSRC UK National Facility Swansea
LTQ Orbitrap XL


James Fyfe
15/05/2014 10:10:38



¹H NMR of 3u, CDCl₃, 400 MHz



¹³C NMR of 3u, CDCl₃, 101 MHz




HRMS of 3u

RL45 MWT=160?
ASAP(SOLID)

EPSRC UK National Facility Swansea
LTQ Orbitrap XL


James Fyfe
15/05/2014 09:56:37




NL:
1.46E7
STRWAT250-PA-HASP#40-59
RT: 0.32-0.48 AV: 20 T: FTMS
+ p APCI corona Full ms
[80.00-1000.00]

NL:
2.08E4
C₁₁ H₁₂ OH:
C₁₁ H₁₃ O₁
p (gss, s/p:40) Chrg 1
R: 100000 Res. Pwr. @FWHM

¹H NMR of 3v, CDCl₃, 500 MHz



¹³C NMR of 3v, CDCl₃, 126 MHz




HRMS of 3v

JM41 MW=196?
C₁₄H₁₂O
(MeCN)/MeOH

EPSRC National Facility Swansea
LTQ Orbitrap XL


Diana Castagna
28/02/2014 07:39:49




NL:
4.27E7
STRWAT184-OA-HNESN#2
RT: 0.26 AV: 1 T: FTMS - p
NSI Full ms [120.00-2000.00]

NL:
2.01E4
C₁₄H₁₁O:
C₁₄H₁₁O₁
p (gss, s /p:40) Chrg -1
R: 100000 Res .Pwr . @FWHM

¹H NMR of 3w, CD₃CN, 500 MHz



¹³C NMR of 3w, CD₃CN, 126 MHz




HRMS of 3w


JM31 MW=176?
ASAP (LIQUID + D/M1)

EPSRC UK National Facility Swansea
LTQ Orbitrap XL


Castagna
28/02/2014 14:35:54




¹H NMR of 7, DMSO-d₆, 400 MHz



¹³C NMR of 7, DMSO-d₆, 101 MHz



¹⁹F NMR of 7, DMSO-d₆, 376 MHz




HRMS of 7


RL85 MW=250?
C₁₃H₈F₂O₃
(MeOH)/MeOH

EPSRC National Facility Swansea
LTQ Orbitrap XL


James Fyfe
10/09/2014 14:33:07



¹H NMR of 8, DMSO-d₆, 400 MHz



¹³C NMR of 8, DMSO-d₆, 101 MHz




HRMS of 8

RL113 MW=195?
C₁₃H₉NO
(MeOH)/MeOH

EPSRC National Facility Swansea
LTQ Orbitrap XL


James Fyfe
10/09/2014 14:15:55




NL:
2.43E7
STRWAT327-OE-HNESN#14-
41 RT: 0.11-0.34 AV: 28 T:
FTMS - p NSI Full ms
[150.00-2000.00]

NL:
2.03E4
C₁₃H₈NO:
C₁₃H₈N₁O₁
p (gss, s /p:40) Chrg -1
R: 100000 Res .Pwr . @FWHM

¹H NMR of 9, CDCl₃, 500 MHz



¹³C NMR of 9, CDCl₃, 126 MHz



HRMS of 9

JF183-1 MW=282?
ASAP(SOLID)

EPSRC National Centre Swansea
LTQ Orbitrap XL

Jamie
24/09/2014 07:48:39

